[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 82 of about 82
1. Aaronson DS, Yamasaki I, Gottschalk A, Speight J, Hsu IC, Pickett B, Roach M 3rd, Shinohara K: Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy. BJU Int; 2009 Sep;104(5):600-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy.
  • OBJECTIVE: To assess our experience with salvage permanent perineal radioactive-seed implantation (SPPI) as a possible therapeutic option for recurrent prostate adenocarcinoma, as salvage therapies for recurrences after definitive external beam radiotherapy (EBRT) for localized adenocarcinoma of the prostate are associated with significant morbidity and biochemical failure.
  • PATIENTS AND METHODS: We retrospectively analysed on patients who had SPPI for localized recurrent prostate adenocarcinoma from 1996 to 2007 after primary treatment with EBRT.
  • Primary outcomes were time to biochemical relapse-free survival, using the Phoenix definition of a prostate-specific antigen (PSA) nadir +2 ng/mL, and cancer-specific survival.
  • Secondary outcomes were the International Prostate Symptom Score (IPSS), the International Index of Erectile Function-5 score (IIEF-5), and complications based on Common Terminology Criteria for Adverse Events (version 3).
  • CONCLUSION: With a short-term follow-up SPPI appears to provide excellent prostate cancer control with an acceptable rate of complications for patients with local recurrence of prostate cancer after EBRT.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Neoplasm Recurrence, Local / radiotherapy. Prostatic Neoplasms / radiotherapy. Salvage Therapy / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Epidemiologic Methods. Humans. Male. Middle Aged. Prostate-Specific Antigen / metabolism. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19245439.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


2. Zacharakis E, Ahmed HU, Ishaq A, Scott R, Illing R, Freeman A, Allen C, Emberton M: The feasibility and safety of high-intensity focused ultrasound as salvage therapy for recurrent prostate cancer following external beam radiotherapy. BJU Int; 2008 Sep;102(7):786-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The feasibility and safety of high-intensity focused ultrasound as salvage therapy for recurrent prostate cancer following external beam radiotherapy.
  • OBJECTIVES: To investigate the use of minimally invasive high-intensity focused ultrasound (HIFU) as a salvage therapy in men with localized prostate cancer recurrence following external beam radiotherapy (EBRT).
  • All men had presumed organ-confined, histologically confirmed recurrent prostate adenocarcinoma following EBRT.
  • [MeSH-major] Adenocarcinoma / therapy. Neoplasm Recurrence, Local / therapy. Prostatic Neoplasms / therapy. Salvage Therapy / instrumentation. Ultrasound, High-Intensity Focused, Transrectal / instrumentation

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18564135.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MRC/ G0701302; United Kingdom / Medical Research Council / / MRC/ G1002509
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


3. Liao CP, Zhong C, Saribekyan G, Bading J, Park R, Conti PS, Moats R, Berns A, Shi W, Zhou Z, Nikitin AY, Roy-Burman P: Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res; 2007 Aug 1;67(15):7525-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence.
  • The application of Cre/loxP technology has resulted in a new generation of conditional mouse models of prostate cancer.
  • Here, we describe the improvement of the conditional Pten deletion model of prostate adenocarcinoma by combining it with either a conditional luciferase or enhanced green fluorescent protein reporter line.
  • By comparing the distribution of phenotypically distinct populations of epithelial cells in cancer tissues, we noted that the degree of hyperplasia of cells with neuroendocrine differentiation significantly increases in the recurrent cancer relative to the primary cancer, a characteristic which may parallel the appearance of a neuroendocrine phenotype in human androgen depletion-independent cancer.
  • These refined models should be useful in the elucidation of mechanisms of prostate cancer progression, and for the development of approaches to preclinical intervention.


Advertisement
4. Pendleton JM, Tan WW, Anai S, Chang M, Hou W, Shiverick KT, Rosser CJ: Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer; 2008 May 11;8:132
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy.
  • BACKGROUND: Data exist that demonstrate isoflavones' potent antiproliferative effects on prostate cancer cells.
  • We evaluated the efficacy of isoflavone in patients with PSA recurrent prostate cancer after prior therapy.
  • CONCLUSION: Dietary intervention with isoflavone supplementation may have biologic activity in men with biochemical recurrent prostate cancer as shown by a decline in the slope of PSA.
  • This study may lend support to the literature that nutritional supplements have biologic activity in prostate cancer and therefore, further studies with these agents in randomized clinical trials should be encouraged.
  • [MeSH-major] Adenocarcinoma / drug therapy. Isoflavones / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Prostate-Specific Antigen / blood. Prostatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. GENISTEIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Cell Res. 1989 Aug;183(2):335-42 [2767154.001]
  • [Cites] J Natl Cancer Inst. 1968 Jan;40(1):43-68 [5635018.001]
  • [Cites] Methods Enzymol. 1991;201:362-70 [1658553.001]
  • [Cites] Ann Intern Med. 1993 May 15;118(10):793-803 [8470854.001]
  • [Cites] Am J Pathol. 1994 Apr;144(4):735-46 [7512791.001]
  • [Cites] Nutr Cancer. 1994;21(2):113-31 [8058523.001]
  • [Cites] J Nutr. 1995 Mar;125(3 Suppl):757S-770S [7884562.001]
  • [Cites] Health Serv Res. 1995 Apr;30(1 Pt 2):197-205 [7721592.001]
  • [Cites] Nutr Cancer. 2005;51(1):32-6 [15749627.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2005;8(2):179-83 [15809670.001]
  • [Cites] Circulation. 2006 Feb 21;113(7):1034-44 [16418439.001]
  • [Cites] Cancer Detect Prev. 2006;30(1):24-33 [16495020.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2172-7 [16609031.001]
  • [Cites] Urology. 2006 Jun;67(6):1257-61 [16765186.001]
  • [Cites] Nutr Cancer. 2006;54(2):232-42 [16898868.001]
  • [Cites] Eur J Cancer. 2006 Nov;42(16):2833-7 [17010601.001]
  • [Cites] J Nutr Biochem. 2007 Jun;18(6):380-90 [16963248.001]
  • [Cites] Clin Chim Acta. 1996 Mar 29;247(1-2):121-42 [8920232.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1035-41 [9169810.001]
  • [Cites] J Urol. 1998 Jun;159(6):2035-9; discussion 2039-40 [9598513.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 May;7(5):391-5 [9610788.001]
  • [Cites] J Urol. 2000 Aug;164(2):567-72 [10893645.001]
  • [Cites] J Steroid Biochem Mol Biol. 2002 Jun;81(2):135-40 [12137802.001]
  • [Cites] Nutr Cancer. 2003;47(2):111-7 [15087261.001]
  • [Cites] Br J Cancer. 1991 Jun;63(6):963-6 [2069852.001]
  • (PMID = 18471323.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00596895
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 4',7-dihydroxy-3,4-dihydroisoflavone; 0 / Isoflavones; 0 / Receptors, Androgen; 531-95-3 / Equol; 6287WC5J2L / daidzein; DH2M523P0H / Genistein; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ PMC2394534
  •  go-up   go-down


5. De E, Pisters LL, Pettaway CA, Scott S, Westney OL: Salvage prostatectomy with bladder neck closure, continent catheterizable stoma and bladder augmentation: feasibility and patient reported continence outcomes at 32 months. J Urol; 2007 Jun;177(6):2200-4; discussion 2204
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The indication for surgery was recurrent adenocarcinoma of the prostate in 10 patients and invasive squamous cell carcinoma of the urethra in 1.
  • [MeSH-major] Adenocarcinoma / surgery. Cystostomy. Prostatectomy. Prostatic Neoplasms / surgery. Salvage Therapy. Urinary Incontinence / surgery

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Urinary Incontinence.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509319.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Eisenberg ML, Shinohara K: Partial salvage cryoablation of the prostate for recurrent prostate cancer after radiotherapy failure. Urology; 2008 Dec;72(6):1315-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Partial salvage cryoablation of the prostate for recurrent prostate cancer after radiotherapy failure.
  • OBJECTIVES: To determine the efficacy of partial cryoablation of the prostate in the salvage setting.
  • METHODS: All patients who were treated between April 2004 and September 2007 for recurrent prostate adenocarcinoma after failure of primary radiotherapy by means of partial cryoablation were identified.
  • One of 10 patients harbored residual carcinoma on routine follow-up biopsy at 1 year, whereas 50% harbored residual benign prostate tissue.
  • CONCLUSIONS: In properly selected patients with a unilateral focus of disease recurrence after radiotherapy, acceptable oncologic results can be achieved with partial cryoablation of the prostate, with low morbidity.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / therapy. Cryosurgery / methods. Prostatic Neoplasms / pathology. Prostatic Neoplasms / radiotherapy. Prostatic Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood. Recurrence. Retrospective Studies. Salvage Therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18597824.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


7. Du KL, Mick R, Busch TM, Zhu TC, Finlay JC, Yu G, Yodh AG, Malkowicz SB, Smith D, Whittington R, Stripp D, Hahn SM: Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer. Lasers Surg Med; 2006 Jun;38(5):427-34
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer.
  • Our group at the University of Pennsylvania has performed extensive studies that demonstrate the feasibility of interstitial PDT for prostate cancer.
  • STUDY DESIGN/MATERIALS AND METHODS: We have treated 16 canines in preclinical studies, and 16 human subjects in a Phase I study, using motexafin lutetium-mediated PDT for recurrent prostate adenocarcinoma.
  • RESULTS: We demonstrate the safe and comprehensive treatment of the prostate using PDT.
  • However, there is significant variability in the dose distribution and the subsequent tissue necrosis throughout the prostate.
  • CONCLUSIONS: PDT is an attractive option for the treatment of prostate adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Metalloporphyrins / administration & dosage. Photochemotherapy. Photosensitizing Agents / administration & dosage. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Animals. Dogs. Dose-Response Relationship, Drug. Hemoglobins / metabolism. Humans. Male. Middle Aged. Necrosis. Neoplasm Recurrence, Local / drug therapy. Oxygen / blood. Prostate / blood supply. Prostate / metabolism. Prostate / pathology. Regional Blood Flow / drug effects

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16788929.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R21 CA88064
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Metalloporphyrins; 0 / Photosensitizing Agents; 0A85BJ22L6 / motexafin lutetium; S88TT14065 / Oxygen
  •  go-up   go-down


8. Fukuhara H, Martuza RL, Rabkin SD, Ito Y, Todo T: Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma. Clin Cancer Res; 2005 Nov 1;11(21):7886-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma.
  • We now report studies demonstrating the potential of G47Delta as a therapeutic modality for prostate cancer in combination with androgen ablation.
  • EXPERIMENTAL DESIGN: The cytopathic activities of G47Delta at low multiplicities of infection was tested in human prostate cancer cell lines LNCaP, PC-3, and DU145 in vitro.
  • TRAMP and HONDA tumors and inhibited the growth of recurrent HONDA tumors that once regressed by androgen ablation therapy.
  • CONCLUSIONS: These results suggest that oncolytic virus therapy with G47Delta can be usefully combined with androgen ablation therapy for the treatment of prostate cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Androgens / metabolism. Genetic Therapy / methods. Genetic Vectors. Oncolytic Viruses / genetics. Prostatic Neoplasms / pathology. Prostatic Neoplasms / therapy. Simplexvirus / genetics

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16278413.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA102139
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens
  •  go-up   go-down


9. Petraki CD, Sfikas CP: Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma. Histol Histopathol; 2007 01;22(1):107-18
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma.
  • The effect of androgen deprivation and other hormonal therapies, radiation therapy, thermal ablation therapies, chemotherapy, and other systemic treatments is evident in the histology of non-neoplastic and neoplastic human prostate gland.
  • Androgen deprivation therapies cause atrophy of non-neoplastic and neoplastic prostatic epithelium, as the result of apoptosis, and are mainly used as a palliative measure in metastatic prostate cancer or as neoadjuvant or adjuvant treatment, in clinically localized prostate cancer.
  • Radiation therapy may be applied in the form of external beam, interstitial implantation (brachytherapy), or a combination, as a mainstay or adjuvant (external beam) treatment in localized prostate cancer.
  • The difficulty of post-radiation prostate needle biopsy interpretation includes the distinction of treatment effect in normal prostatic tissue from recurrent or residual tumour.
  • [MeSH-major] Adenocarcinoma / therapy. Prostate / drug effects. Prostate / pathology. Prostate / radiation effects. Prostatic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17128417.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Androgens; 0 / Antineoplastic Agents; 0 / Estrogens; EC 1.3.1.22 / Cholestenone 5 alpha-Reductase
  • [Number-of-references] 95
  •  go-up   go-down


10. Galosi AB, Lugnani F, Muzzonigro G: Salvage cryosurgery for recurrent prostate carcinoma after radiotherapy. J Endourol; 2007 Jan;21(1):1-7
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage cryosurgery for recurrent prostate carcinoma after radiotherapy.
  • Cryotherapy is a salvage treatment for patients with biopsy-proved prostatic adenocarcinoma recurrent after radiotherapy.
  • Proper sampling, labeling, and analysis of prostate biopsies allows prompt diagnosis, identification of important prognostic parameters, and planning of an appropriate therapeutic strategy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17263599.001).
  • [ISSN] 0892-7790
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 36
  •  go-up   go-down


11. Manyak MJ: Indium-111 capromab pendetide in the management of recurrent prostate cancer. Expert Rev Anticancer Ther; 2008 Feb;8(2):175-81
MedlinePlus Health Information. consumer health - Prostate Cancer Screening.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indium-111 capromab pendetide in the management of recurrent prostate cancer.
  • The provision of accurate prognostic information is a long-standing goal for effective management of prostate adenocarcinoma.
  • Nontargeted imaging modalities are less efficient at detecting slow-growing prostate cancers.
  • Prostate-specific membrane antigen has emerged as a superior biomarker, especially for the evaluation of metastatic spread.
  • Advances in imaging technology have focused clinical interest on indium-111 capromab ((111)In capromab) pendetide, a radioimmunoconjugate that detects prostate-specific membrane antigen expression in vivo.
  • In long-term outcomes studies, fused (111)In capromab pendetide scans have delivered significant benefits for patient selection and improved treatment of prostate cancer.
  • [MeSH-major] Antibodies, Monoclonal. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / radionuclide imaging. Prostate-Specific Antigen / blood. Tomography, Emission-Computed, Single-Photon
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / therapy. Combined Modality Therapy. Humans. Immunohistochemistry. Indium Radioisotopes. Male. Neoplasm Staging. Prognosis. Prostatic Neoplasms / mortality. Prostatic Neoplasms / pathology. Prostatic Neoplasms / therapy. Sensitivity and Specificity. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18279057.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Indium Radioisotopes; 145464-28-4 / Capromab Pendetide; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 41
  •  go-up   go-down


12. Tu WH, Jensen K, Freiha F, Liao JC: A case of prostatic adenocarcinoma recurrence presenting as ductal carcinoma of the prostate. Nat Clin Pract Urol; 2008 Jan;5(1):55-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of prostatic adenocarcinoma recurrence presenting as ductal carcinoma of the prostate.
  • BACKGROUND: A 61-year-old man with a history of recurrent prostate cancer presented with obstructive urinary symptoms.
  • He had been diagnosed with locally invasive adenocarcinoma of the prostate 10 years previously and treated with neoadjuvant hormonal and external beam radiation therapies.
  • DIAGNOSIS: The patient underwent transurethral resection of the prostate.
  • Pathologic analysis confirmed the presence of ductal carcinoma of the prostate.
  • The patient was started on docetaxel-based chemotherapy for hormone refractory recurrence of prostate cancer as ductal carcinoma of the prostate.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18185514.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Kirkpatrick JP, Anscher MS: Radiotherapy for locally recurrent prostate cancer. Clin Adv Hematol Oncol; 2005 Dec;3(12):933-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy for locally recurrent prostate cancer.
  • The optimal treatment of the patient at high risk for local recurrence of prostate cancer after radical prostatectomy is controversial.
  • Similarly, there is much controversy over how to treat patients with a rising prostate-specific antigen (PSA), but without overt metastases, after radical prostatectomy.
  • Making this distinction is critical, since patients with local disease may be cured with radiation therapy to the prostate bed, whereas those with metastatic disease will require a different treatment approach.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Biomarkers, Tumor / blood. Neoplasm Recurrence, Local / radiotherapy. Prostate-Specific Antigen / blood. Prostatic Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16555435.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 114
  •  go-up   go-down


14. Maeda T, Tateishi U, Komiyama M, Fujimoto H, Watanabe S, Terauchi T, Moriyama N, Arai Y, Sugimura K, Kakizoe T: Distant metastasis of prostate cancer: early detection of recurrent tumor with dual-phase carbon-11 choline positron emission tomography/computed tomography in two cases. Jpn J Clin Oncol; 2006 Sep;36(9):598-601
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distant metastasis of prostate cancer: early detection of recurrent tumor with dual-phase carbon-11 choline positron emission tomography/computed tomography in two cases.
  • Several types of recurrence may be detected by radiologic assessment after treatment in patients with prostate cancer.
  • We report two patients who underwent hormone therapy or surgical resection for prostate cancer.
  • In one patient, recurrent tumor of the supraclavicular node (6 mm) diminished in size after subsequent hormone therapy.
  • Surgical resection of recurrent tumor of the lung (12 mm) was performed in the other patient, the pathology of which confirmed the metastatic adenocarcinoma derived from the prostate.
  • The recurrent tumor can be correctly detected by dual-phase whole body [C-11] choline positron emission tomography/computed tomography.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / radionuclide imaging. Lymph Nodes / pathology. Lymphatic Metastasis / radionuclide imaging. Pelvic Neoplasms / radionuclide imaging. Positron-Emission Tomography. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Agents, Hormonal / therapeutic use. Carbon Radioisotopes. Choline. Early Diagnosis. Humans. Male. Prostate-Specific Antigen / blood. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16844733.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Carbon Radioisotopes; EC 3.4.21.77 / Prostate-Specific Antigen; N91BDP6H0X / Choline
  •  go-up   go-down


15. Verigos K, Stripp DC, Mick R, Zhu TC, Whittington R, Smith D, Dimofte A, Finlay J, Busch TM, Tochner ZA, Malkowicz S, Glatstein E, Hahn SM: Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer. J Environ Pathol Toxicol Oncol; 2006;25(1-2):373-87
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer.
  • Locally recurrent prostate cancer after treatment with radiation therapy is a clinical problem with few acceptable treatments.
  • A Phase I trial of interstitial PDT with the photosensitizer Motexafin lutetium was initiated in men with locally recurrent prostate cancer.
  • Other objectives include evaluation of Motexafin lutetium uptake from prostate tissue using a spectrofluorometric assay and evaluation of optical properties in the human prostate.
  • Fifteen men with biopsy-proven locally recurrent prostate cancer and no evidence of distant metastatic disease have been enrolled and 14 have been treated.
  • Prostate biopsies were obtained before and after light delivery for spectrofluorometric measurements of photosensitizer uptake.
  • Measurements of Motexafin lutetium demonstrated the presence of photosensitizer in prostate tissue from all patients.
  • Optical property measurements demonstrated substantial heterogeneity in the optical properties of the human prostate gland which supports the use of individualized treatment planning for prostate PDT.
  • [MeSH-major] Adenocarcinoma / drug therapy. Metalloporphyrins / therapeutic use. Photochemotherapy / adverse effects. Photosensitizing Agents / therapeutic use. Prostatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566729.001).
  • [ISSN] 0731-8898
  • [Journal-full-title] Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  • [ISO-abbreviation] J. Environ. Pathol. Toxicol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-88064
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Metalloporphyrins; 0 / Photosensitizing Agents; 0A85BJ22L6 / motexafin lutetium
  •  go-up   go-down


16. Heijmink SW, Scheenen TW, Fütterer JJ, Klomp DW, Heesakkers RA, Hulsbergen-van de Kaa CA, van Lin EN, Heerschap A, Barentsz JO: Prostate and lymph node proton magnetic resonance (MR) spectroscopic imaging with external array coils at 3 T to detect recurrent prostate cancer after radiation therapy. Invest Radiol; 2007 Jun;42(6):420-7
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate and lymph node proton magnetic resonance (MR) spectroscopic imaging with external array coils at 3 T to detect recurrent prostate cancer after radiation therapy.
  • In a patient suspected of having recurrent prostate cancer after radiation therapy, we demonstrate the feasibility of noninvasive proton magnetic resonance spectroscopic (1H-MRS) imaging of the prostate and a lymph node at 3 T using a matrix of external surface coils.
  • With 1H-MRS imaging, high choline with low citrate signal was observed in the prostate, and in the lymph node a signal of choline-containing compounds was identified.
  • Subsequent histopathological analysis of systematic transrectal ultrasound-guided prostate biopsy and computed tomography-guided biopsy of the lymph node confirmed the presence of prostate cancer in both.
  • [MeSH-major] Adenocarcinoma / pathology. Magnetic Resonance Spectroscopy / methods. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17507814.001).
  • [ISSN] 0020-9996
  • [Journal-full-title] Investigative radiology
  • [ISO-abbreviation] Invest Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] N91BDP6H0X / Choline
  •  go-up   go-down


17. Cheung E, Pinski J, Dorff T, Groshen S, Quinn DI, Reynolds CP, Maurer BJ, Lara PN Jr, Tsao-Wei DD, Twardowski P, Chatta G, McNamara M, Gandara DR: Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial. Clin Genitourin Cancer; 2009 Jan;7(1):43-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial.
  • We conducted a phase II trial of oral fenretinide in patients with biochemically recurrent prostate cancer.
  • PATIENTS AND METHODS: Eligible patients had histologically confirmed prostate cancer and a confirmed rising prostate-specific antigen (PSA) >or= 2 ng/mL following either radical prostatectomy and/or pelvic radiation therapy, without clinical or radiographic evidence of metastasis.
  • CONCLUSION: Although well-tolerated, oral fenretinide did not meet prespecified PSA criteria for response in biochemically recurrent prostate cancer; however, 30% of patients had SD, which suggests modest single-agent clinical activity.
  • [MeSH-major] Adenocarcinoma / drug therapy. Androgen Antagonists / therapeutic use. Antineoplastic Agents / therapeutic use. Fenretinide / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Prostatic Neoplasms / drug therapy


18. Liao CP, Liang M, Cohen MB, Flesken-Nikitin A, Jeong JH, Nikitin AY, Roy-Burman P: Mouse prostate cancer cell lines established from primary and postcastration recurrent tumors. Horm Cancer; 2010 Feb;1(1):44-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mouse prostate cancer cell lines established from primary and postcastration recurrent tumors.
  • The clinical course of prostate cancer is grouped into two broad phases.
  • The first phase, which is the growth of the androgen-dependent cancer (AD-Ca) responds well to androgen depletion treatment while the second phase, that could be termed as androgen depletion-independent cancer (ADI-Ca) does not.
  • We used two separate prostate tumors, one AD-Ca and one ADI-Ca from the conditional Pten deletion mouse model to generate from each a pair of cell lines.
  • The AD-Ca cell lines (E2 and E4) and the ADI-Ca cell lines (cE1 and cE2) display bi-allelic deletion at the Pten gene locus, an event which is specific for the prostate epithelium for this mouse model, and a fairly similar level of expression of the androgen receptor (AR).
  • The AD-Ca cell lines (E series) grow slowly in the absence of androgen, and, unlike cE cells, do not show increased AR expression when maintained in the absence of androgen.
  • These new cell lines are promising models for the elucidation of the androgen metabolism and their role in prostate cancer.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mech Dev. 2001 Mar;101(1-2):61-9 [11231059.001]
  • [Cites] Prostate. 2010 Apr 1;70(5):457-66 [19902465.001]
  • [Cites] Mol Cancer Res. 2002 Dec;1(2):113-21 [12496358.001]
  • [Cites] Prostate. 2003 Nov 1;57(3):205-25 [14518029.001]
  • [Cites] Cancer Cell. 2003 Sep;4(3):209-21 [14522255.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2270-305 [15026373.001]
  • [Cites] PLoS Biol. 2003 Dec;1(3):E59 [14691534.001]
  • [Cites] Endocr Rev. 2004 Apr;25(2):276-308 [15082523.001]
  • [Cites] Endocr Relat Cancer. 2004 Jun;11(2):225-54 [15163300.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3325-30 [9269988.001]
  • [Cites] J Biol Chem. 1998 Jul 10;273(28):17618-25 [9651357.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2493-500 [9815652.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5730-9 [15994948.001]
  • [Cites] Cancer Biol Ther. 2005 Jan;4(1):4-5 [16052746.001]
  • [Cites] Am J Pathol. 2006 Aug;169(2):682-96 [16877366.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7889-98 [16912162.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):148-58 [17170745.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2490-6 [17363566.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5683-90 [17553900.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5789-97 [17575146.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6083-91 [17616663.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7525-33 [17671224.001]
  • [Cites] Prostate. 2007 Dec 1;67(16):1761-9 [17929277.001]
  • [Cites] J Biomed Opt. 2007 Nov-Dec;12(6):064007 [18163823.001]
  • [Cites] Nature. 2008 Dec 11;456(7223):804-8 [18946470.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Aug;1(3):161-6 [19138951.001]
  • [Cites] Nat Med. 2004 Jan;10(1):33-9 [14702632.001]
  • [Cites] J Am Soc Nephrol. 2009 Apr;20(4):765-76 [19297557.001]
  • [Cites] Lancet Oncol. 2009 Oct;10(10):981-91 [19796750.001]
  • [Cites] Cancer Res. 2009 Oct 15;69(20):8141-9 [19808968.001]
  • [Cites] Prostate. 2010 Jan 1;70(1):100-12 [19760632.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3550-5 [11325816.001]
  • (PMID = 20631921.001).
  • [ISSN] 1868-8500
  • [Journal-full-title] Hormones & cancer
  • [ISO-abbreviation] Horm Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA113392-05; United States / NCI NIH HHS / CA / R01 CA059705-17; United States / NCI NIH HHS / CA / R01 CA059705; United States / NCI NIH HHS / CA / R01 CA096823-07; United States / NCI NIH HHS / CA / R56 CA096823; United States / NCI NIH HHS / CA / R01 CA96823; United States / NCI NIH HHS / CA / R01 CA096823; United States / NCI NIH HHS / CA / CA096823-07; United States / NCI NIH HHS / CA / R01 CA59705; United States / NCI NIH HHS / CA / CA113392-05; United States / NCI NIH HHS / CA / R01 CA113392; United States / NCI NIH HHS / CA / CA059705-17
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Keywords] NOTNLM ; Conditional Pten-deletion mouse model of prostate adenocarcinoma / androgen-dependent and androgen depletion-independent prostate cancer / mouse prostate cancer cell lines / prostate sarcomatoid carcinoma
  •  go-up   go-down


19. Bañez LL, Blake GW, McLeod DG, Crawford ED, Moul JW: Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up. BJU Int; 2009 Aug;104(3):310-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.
  • OBJECTIVE: To compare the efficacy and tolerability of peripheral androgen blockade using combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for treating biochemical relapse after the definitive management of prostate adenocarcinoma.
  • PATIENTS AND METHODS: Fifty-six men treated for biochemical relapse of prostate cancer were enrolled prospectively in a phase II trial at the Walter Reed Army Medical Center from 1997 to 2001.
  • Thirty-six men were treated with flutamide (125 mg twice daily) and finasteride (5 mg twice daily), and 20 men received low-dose flutamide only after biochemical recurrence (prostate-specific antigen, PSA, level > or =0.4 ng/mL).
  • CONCLUSIONS: Our analysis suggests the therapeutic value of low-dose flutamide alone or combined with finasteride as first-line agents in a possible graduated approach for treating PSA-only recurrent prostate cancer.
  • [MeSH-minor] Aged. Androgen Antagonists / administration & dosage. Antineoplastic Agents, Hormonal / administration & dosage. Epidemiologic Methods. Humans. Male. Middle Aged. Prostate-Specific Antigen / metabolism. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FINASTERIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19239458.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; 57GNO57U7G / Finasteride; 76W6J0943E / Flutamide; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


20. Mehra R, Han B, Tomlins SA, Wang L, Menon A, Wasco MJ, Shen R, Montie JE, Chinnaiyan AM, Shah RB: Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res; 2007 Sep 1;67(17):7991-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases.
  • Recurrent gene fusions between the androgen-regulated gene TMPRSS2 and the ETS family transcription factors ERG, ETV1, and ETV4 have been identified in the majority of prostate adenocarcinomas (PCA).
  • [MeSH-major] Adenocarcinoma / genetics. Genetic Heterogeneity. Neoplasms, Multiple Primary / genetics. Prostatic Neoplasms / genetics. Serine Endopeptidases / genetics. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17804708.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA69568; United States / NCI NIH HHS / PC / PC040517; United States / NCI NIH HHS / CA / U01 CA111275-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / TMPRSS2 protein, human
  •  go-up   go-down


21. Bermudo R, Abia D, Ferrer B, Nayach I, Benguria A, Zaballos A, del Rey J, Miró R, Campo E, Martínez-A C, Ortiz AR, Fernández PL, Thomson TM: Co-regulation analysis of closely linked genes identifies a highly recurrent gain on chromosome 17q25.3 in prostate cancer. BMC Cancer; 2008;8:315
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Co-regulation analysis of closely linked genes identifies a highly recurrent gain on chromosome 17q25.3 in prostate cancer.
  • BACKGROUND: Transcriptional profiling of prostate cancer (PC) has unveiled new markers of neoplasia and allowed insights into mechanisms underlying this disease.
  • Here we describe transcriptional signatures identifying distinct normal and tumoral prostate tissue compartments, and the inference and demonstration of a new, highly recurrent copy number gain on chromosome 17q25.3.
  • METHODS: We have applied transcriptional profiling to tumoral and non-tumoral prostate samples with relatively homogeneous epithelial representations as well as pure stromal tissue from peripheral prostate and cultured cell lines, followed by quantitative RT-PCR validations and immunohistochemical analysis.
  • RESULTS: The transcriptomic analysis has allowed us to identify signatures corresponding to non-tumoral luminal and tumoral epithelium, basal epithelial cells, and prostate stromal tissue.
  • Therefore, transcriptomic studies of carefully selected samples can unveil new diagnostic markers and transcriptional signatures highly specific of PC, and lead to the discovery of novel genomic abnormalities that may provide additional insights into the causes and mechanisms of prostate cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Chromosomes, Human, Pair 17. Gene Expression Regulation, Neoplastic. Prostatic Neoplasms / genetics

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prostate. 1999 Dec 1;41(4):275-80 [10544301.001]
  • [Cites] Nat Biotechnol. 2008 Mar;26(3):305-12 [18327244.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):399-406 [11159178.001]
  • [Cites] Prostate. 2001 Feb 15;46(3):249-56 [11170154.001]
  • [Cites] Oncogene. 2001 Jan 4;20(1):48-57 [11244503.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5692-6 [11479199.001]
  • [Cites] Nature. 2001 Aug 23;412(6849):822-6 [11518967.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6331-4 [11522620.001]
  • [Cites] BJU Int. 2002 Feb;89(3):310-6 [11856117.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):2169-80 [12057920.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):203-9 [12086878.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4499-506 [12154061.001]
  • [Cites] Eur Urol. 2002 Mar;41(3):328-34 [12180237.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6A):3149-57 [12530058.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Curr Opin Cell Biol. 2003 Oct;15(5):583-9 [14519393.001]
  • [Cites] Urology. 2003 Nov;62(5 Suppl 1):11-20 [14607213.001]
  • [Cites] Genome Res. 2004 Jan;14(1):179-87 [14672980.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):615-20 [14722351.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6 [14711987.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):5963-72 [15342375.001]
  • [Cites] Oncogene. 1996 Jan 4;12(1):53-62 [8552399.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Jun;6(6):443-50 [9184779.001]
  • [Cites] Cancer Res. 1998 Jan 1;58(1):23-8 [9426051.001]
  • [Cites] J Biol Chem. 2005 Feb 11;280(6):4483-90 [15574414.001]
  • [Cites] Genomics. 2005 Mar;85(3):401-12 [15718107.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):725-30 [16079851.001]
  • [Cites] BMC Genomics. 2005;6:109 [16107210.001]
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] Br J Cancer. 2006 Jan 16;94(1):128-35 [16404366.001]
  • [Cites] Cell Cycle. 2006 Jan;5(2):138-41 [16357539.001]
  • [Cites] Hum Pathol. 2006 Apr;37(4):401-9 [16564913.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):5977-80 [16778164.001]
  • [Cites] J Pathol. 2006 Aug;209(4):492-500 [16721726.001]
  • [Cites] Int J Cancer. 2006 Sep 15;119(6):1322-9 [16642477.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Sep;7(9):644-56 [16896351.001]
  • [Cites] J Biol Chem. 2007 Feb 2;282(5):2776-84 [17145757.001]
  • [Cites] N Engl J Med. 2008 Feb 28;358(9):910-9 [18199855.001]
  • [Cites] Nat Genet. 2008 Mar;40(3):310-5 [18264096.001]
  • [Cites] Nat Genet. 2008 Mar;40(3):316-21 [18264097.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1677-82 [10749139.001]
  • (PMID = 18973659.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2585097
  •  go-up   go-down


22. Poissonnier L, Murat FJ, Belot A, Bouvier R, Rabilloud M, Rouviere O, Chapelon JY, Gelet A: [Locally recurrent prostatic adenocarcinoma after exclusive radiotherapy: results of high intensity focused ultrasound]. Prog Urol; 2008 Apr;18(4):223-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Locally recurrent prostatic adenocarcinoma after exclusive radiotherapy: results of high intensity focused ultrasound].
  • OBJECTIVES: To determine the efficacy and adverse effects of high intensity focused ultrasound (HIFU) for the treatment of local recurrence of prostate cancer after exclusive external beam radiotherapy.
  • [MeSH-major] Adenocarcinoma / therapy. Brachytherapy. Neoplasm Recurrence, Local / therapy. Prostatic Neoplasms / therapy. Ultrasound, High-Intensity Focused, Transrectal

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18501302.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


23. Lledó García E, Jara Rascón J, Subirá Rós D, Herranz Amo F, Martínez-Salamanca JI, Hernández Fernández C: [Scientific evidence on the use of high-intensity focal ultrasound (HIFU) in the treatment of prostatic carcinoma]. Actas Urol Esp; 2005 Feb;29(2):131-7
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Evidencia científica actual sobre la utilidad del ultrasonido de alta intensidad (HIFU) en el tratamiento del adenocarcinoma prostático.
  • RESULTS: Publications available are focused on two main indications of the therapy: first step of management of PC and salvage therapy for locally recurrent PC after external beam radiotherapy.
  • [MeSH-major] Adenocarcinoma / therapy. Prostatic Neoplasms / therapy. Ultrasound, High-Intensity Focused, Transrectal / economics
  • [MeSH-minor] Clinical Trials as Topic. Cost-Benefit Analysis. Evidence-Based Medicine. Humans. Male. Prostate-Specific Antigen / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15881912.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 22
  •  go-up   go-down


24. Pontones Moreno JL, Morera Martínez JF, Vera Donoso CD, Jiménez Cruz JF: [Cryosurgery in the management of prostate cancer]. Actas Urol Esp; 2007 Mar;31(3):211-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cryosurgery in the management of prostate cancer].
  • [Transliterated title] Criocirugía en el tratamiento del cáncer de próstata.
  • This article reviews the current status of the prostatic cryosurgery in the management of patients with prostate cancer.
  • Using transrectal high-resolution ultrasound imaging, prostate cryotherapy is delivered with multiple ultrathin (17-gauge) cryo-needles, via percutaneous transperineal approach.
  • The extent of freezing can be precisely controlled and monitored with thermic devices, tissue destruction is monitored with real-time visualization of the prostate and surrounding structures, and urethral warming is used to avoid urethral sloughing.
  • The ability of prostate-specific antigen (PSA) to predict long-term outcome after cryotherapy for localized prostate cancer is not well known because experience with this treatment modality is still limited; however, it seems that a PSA value of 0.5 ng/ml or less after 6 months or longer after cryotherapy would be associated with a high probability (greater than 95%) of negative post-treatment biopsy.
  • Cryosurgery could also be an option of treatment for men with recurrent local disease who have undergone radiotherapy or radical prostatectomy.
  • The favorable side effect profile and preliminary oncologic and funtional results could suggest that cryosurgery will have a role in the minimally invasive management of selected patients with prostate cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Cryosurgery. Prostatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17658150.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 90
  •  go-up   go-down


25. Xiao GQ, Huan Y, Stone N, Stock R, Unger PD: Histological patterns and associated PSA levels for prostatic adenocarcinoma following brachytherapy. Pathol Res Pract; 2009;205(12):843-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological patterns and associated PSA levels for prostatic adenocarcinoma following brachytherapy.
  • A total of 60 patients with prostatic adenocarcinoma treated with brachytherapy between 1993 and 2003, who had at least one positive post-radiation biopsy, were evaluated for their morphologic patterns as well as the associated PSA levels.
  • An increase in the Gleason's score in recurrent carcinoma was also noted in 14% of the cases.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy. Neoplasm Recurrence, Local. Prostate-Specific Antigen / blood. Prostatic Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19646822.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


26. Wachter S, Tomek S, Kurtaran A, Wachter-Gerstner N, Djavan B, Becherer A, Mitterhauser M, Dobrozemsky G, Li S, Pötter R, Dudczak R, Kletter K: 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol; 2006 Jun 1;24(16):2513-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer.
  • PATIENTS AND METHODS: Fifty prostate cancer patients with elevated/increasing serum prostate-specific antigen levels after radical therapy underwent whole-body AC PET.
  • This is particularly true in patients with AC uptake in the prostate region.
  • [MeSH-minor] Acetates. Adenocarcinoma / radiography. Adenocarcinoma / radionuclide imaging. Adenocarcinoma / secondary. Aged. Aged, 80 and over. Carbon Radioisotopes. Feasibility Studies. Humans. Image Processing, Computer-Assisted. Male. Middle Aged. Prostatectomy. Retrospective Studies

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16636343.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acetates; 0 / Carbon Radioisotopes
  •  go-up   go-down


27. Sanjurjo S, Hamida W, Letesson G, Hustinx R, Gillet P, Andrianne R: [Intraoperative scintigraphic visualization of a single rib metastasis from operated prostatic adenocarcinoma]. Prog Urol; 2008 Jun;18(6):402-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraoperative scintigraphic visualization of a single rib metastasis from operated prostatic adenocarcinoma].
  • We present a case of a lonely bone lesion after a prostatic adenocarcinoma with recurrent increased PSA.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Adenocarcinoma / secondary. Bone Neoplasms / radionuclide imaging. Bone Neoplasms / secondary. Prostatic Neoplasms. Ribs
  • [MeSH-minor] Humans. Intraoperative Care. Male. Middle Aged. Prostate-Specific Antigen / blood. Radiopharmaceuticals. Technetium Tc 99m Medronate

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18558331.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; EC 3.4.21.77 / Prostate-Specific Antigen; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


28. Yi SK, Yoder M, Zaner K, Hirsch AE: Palliative radiation therapy of symptomatic recurrent bladder cancer. Pain Physician; 2007 Mar;10(2):285-90
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative radiation therapy of symptomatic recurrent bladder cancer.
  • There are also data that support RT palliation for locally advanced or recurrent rectal, prostate, and gynecological cancers.
  • With regard to bladder cancer there is some evidence of the benefit of palliative RT for the control of urinary symptoms and hematuria; however, there is little evidence for the use of palliative RT for pain associated with locally recurrent bladder cancer.
  • We report a case of locally advanced recurrent bladder cancer which was refractory to medical pain management, and was found to be highly responsive to palliative RT.
  • CASE REPORT: An 80-year-old woman with recurrent bladder cancer and intractable pelvic pain refractory to oral and transdermal pain medications, received palliative pelvic RT to a dose of 50 Gy (5000 cGy) in 25 fractions with complete resolution of pain.
  • The patient was originally found to have dysuria, frequency, and hematuria, secondary to an invasive high grade transitional cell carcinoma of the bladder with an adenocarcinoma component, AJCC pT2b N1 M0 Stage IV, for which she underwent a radical cystectomy, total abdominal hysterectomy, bilateral salpingo-oophorectomy, partial vaginectomy, and ileal conduit reconstruction.
  • There is little data that we are aware of on the use of RT for pain control with patients that have recurrent, locally advanced bladder cancer.
  • RT is an excellent option for pain management in recurrent bladder cancer and should be offered to patients whose pain is not otherwise optimally controlled.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Pain / radiotherapy. Palliative Care / methods. Urinary Bladder Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17387350.001).
  • [ISSN] 1533-3159
  • [Journal-full-title] Pain physician
  • [ISO-abbreviation] Pain Physician
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Zellweger T, Ninck C, Bloch M, Mirlacher M, Koivisto PA, Helin HJ, Mihatsch MJ, Gasser TC, Bubendorf L: Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer; 2005 Feb 10;113(4):619-28
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression patterns of potential therapeutic targets in prostate cancer.
  • Androgen withdrawal is the only effective therapy for patients with advanced prostate cancer, but progression to androgen independence ultimately occurs in almost all patients.
  • Here, we aimed to evaluate the expression of potential therapeutic targets in advanced prostate cancer.
  • A tissue microarray (TMA) containing samples from 535 tissue blocks was constructed, including benign prostatic hyperplasia as controls (n = 65), prostatic intraepithelial neoplasia (PIN; n = 78), clinically localized prostate cancers (n = 181), as well as hormone-refractory local recurrences (n = 120) and distant metastases (n = 91).
  • Significant overexpression in hormone-refractory prostate cancer and metastatic tissue compared to localized prostate cancer was found for Ki67 (64% vs. 9%), Bcl-2 (11% vs. 1%), p53 (35% vs. 4%), Syndecan-1 (38% vs. 3%), EGFR (16% vs. 1%) and HER2/neu (16% vs. 0%).
  • Taken together, p53, Bcl-2, Syndecan-1, EGFR and HER2/neu are preferentially expressed in hormone-refractory and metastatic prostate cancer.
  • Treatment decisions should not be based on findings in primary tumors but rather on tissues from recurrent or metastatic lesions.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / metabolism. Neoplasms, Hormone-Dependent / metabolism. Prostatic Neoplasms / metabolism
  • [MeSH-minor] Humans. Immunoenzyme Techniques. Male. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Prostate / metabolism. Prostate / pathology. Prostatic Hyperplasia / metabolism. Prostatic Hyperplasia / pathology. Prostatic Intraepithelial Neoplasia / metabolism. Prostatic Intraepithelial Neoplasia / pathology


30. Feng S, Agoulnik IU, Bogatcheva NV, Kamat AA, Kwabi-Addo B, Li R, Ayala G, Ittmann MM, Agoulnik AI: Relaxin promotes prostate cancer progression. Clin Cancer Res; 2007 Mar 15;13(6):1695-702
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relaxin promotes prostate cancer progression.
  • PURPOSE: To understand the role of relaxin peptide in prostate cancer, we analyzed the expression of relaxin and its receptor in human prostate cancer samples, the effects of relaxin signaling on cancer cell phenotype in vitro, and the effects of increased serum relaxin concentrations on cancer progression in vivo.
  • The effect of transgenic relaxin overexpression [Tg(Rln1)] on cancer growth and survival was evaluated in autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP).
  • RESULTS: The relaxin mRNA expression was significantly higher in recurrent prostate cancer samples.
  • CONCLUSIONS: Relaxin signaling plays a role in prostate cancer progression.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Guide to Pharmacology. gene/protein/disease-specific - RXFP1 receptor - data and references .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17363522.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA118362-01A1; United States / NCI NIH HHS / CA / R21 CA118362; United States / NCI NIH HHS / CA / 5 P50 CA58204; United States / NCI NIH HHS / CA / R21 CA118362-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / RLN1 protein, human; 0 / RXFP1 protein, human; 0 / Receptors, G-Protein-Coupled; 0 / Receptors, Peptide; 9002-69-1 / Relaxin
  •  go-up   go-down


31. Schmid DT, John H, Zweifel R, Cservenyak T, Westera G, Goerres GW, von Schulthess GK, Hany TF: Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology; 2005 May;235(2):623-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorocholine PET/CT in patients with prostate cancer: initial experience.
  • Patients with newly diagnosed prostate cancer and patients suspected of having recurrent prostate cancer were prospectively evaluated with fluorine 18 fluorocholine (FCH) combined in-line positron emission tomography (PET) and computed tomography (CT).
  • In nine patients evaluated at initial staging, histologic findings of the resected prostate were compared to FCH uptake.
  • Differentiation of benign hyperplasia from cancerous prostate lesions was not possible with FCH PET/CT.
  • However, in patients with recurrent prostate cancer, FCH PET/CT is a promising imaging modality for detecting local recurrence and lymph node metastases.
  • [MeSH-major] Adenocarcinoma / diagnosis. Fluorine Radioisotopes. Image Enhancement. Image Interpretation, Computer-Assisted. Neoplasm Recurrence, Local / diagnosis. Positron-Emission Tomography. Prostatic Neoplasms / diagnosis. Quaternary Ammonium Compounds. Tomography, X-Ray Computed
  • [MeSH-minor] Aged. Aged, 80 and over. Bone Neoplasms / diagnosis. Bone Neoplasms / pathology. Bone Neoplasms / secondary. Humans. Male. Middle Aged. Neoplasm Staging. Pelvic Neoplasms / diagnosis. Pelvic Neoplasms / pathology. Pelvic Neoplasms / secondary. Prostate / pathology. Sensitivity and Specificity. Tissue Distribution

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2005.
  • (PMID = 15858102.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes; 0 / Quaternary Ammonium Compounds; 0 / fluoromethyl dimethyl-2-hydroxyethylammonium
  •  go-up   go-down


32. Mackinnon AC, Yan BC, Joseph LJ, Al-Ahmadie HA: Molecular biology underlying the clinical heterogeneity of prostate cancer: an update. Arch Pathol Lab Med; 2009 Jul;133(7):1033-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular biology underlying the clinical heterogeneity of prostate cancer: an update.
  • CONTEXT: Recent studies have uncovered a number of possible mechanisms by which prostate cancers can become resistant to systemic androgen deprivation, most involving androgen-independent reactivation of the androgen receptor.
  • Genome-wide expression analysis with microarrays has identified a wide array of genes that are differentially expressed in metastatic prostate cancers compared to primary nonrecurrent tumors.
  • Recently, recurrent gene fusions between TMPRSS2 and ETS family genes have been identified and extensively studied for their role in prostatic carcinoma.
  • OBJECTIVE: To review the recent developments in the molecular biology of prostate cancer, including those pertaining to the androgen receptor and the newly identified TMPRSS2-related translocations.
  • CONCLUSIONS: Prostatic adenocarcinoma is a heterogeneous group of neoplasms with a broad spectrum of pathologic and molecular characteristics and clinical behaviors.
  • Multiple translocations of members of the ETS oncogene family are present in approximately half of clinically localized prostate cancers.
  • TMPRSS2:ERG gene rearrangement appears to be an early event in prostate cancer and is not observed in benign or hyperplastic prostatic epithelium.
  • The relationship between TMPRSS2:ERG gene rearrangement and other morphologic and prognostic parameters of prostate cancer is still unclear.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Pathol Lab Med. 2010 Jul;134(7):964-5; author reply 965 [20586617.001]
  • (PMID = 19642730.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / Receptors, Androgen; 0 / TMPRSS2-ERG fusion protein, human; 0 / TMPRSS2-ETS fusion protein, human
  • [Number-of-references] 119
  •  go-up   go-down


33. Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE, Shah RB, Rubin MA, Wei JT, Chinnaiyan AM: Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia; 2006 Oct;8(10):885-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
  • We recently reported the identification of recurrent gene fusions in the majority of prostate cancers involving the 5' untranslated region of the androgen-regulated gene TMPRSS2 and the ETS family members ERG, ETV1, and ETV4.
  • Here we report the noninvasive detection of these gene fusions in the urine of patients with clinically localized prostate cancer.
  • By quantitative polymerase chain reaction, we assessed the expression of ERG and TMPRSS2:ERG transcripts in urine samples obtained after prostatic massage from 19 patients (11 prebiopsy and 8 pre-radical prostatectomy) with prostate cancer.
  • Importantly, by fluorescence in situ hybridization, we confirmed the presence or the absence of TMPRSS2:ERG gene fusions in matched prostate cancer tissue samples from three of three patients with fusion transcripts in their urine and from two of two patients without fusion transcripts in their urine.
  • These results demonstrate that TMPRSS2:ERG gene fusions can be detected in the urine of patients with prostate cancer and support larger studies on prospective cohorts for noninvasive detection of prostate cancer.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2001 Feb;158(2):419-29 [11159180.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):245-50 [11902580.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Expert Rev Mol Diagn. 2003 Jul;3(4):507-19 [12877389.001]
  • [Cites] Nature. 1994 Nov 10;372(6502):143-9 [7969446.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8347-51 [16951141.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3396-400 [16585160.001]
  • [Cites] Neoplasia. 2006 Feb;8(2):153-62 [16611408.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):717-9 [16575875.001]
  • [Cites] Neoplasia. 2006 Jun;8(6):465-9 [16820092.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8337-41 [16951139.001]
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • (PMID = 17059688.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA069568; United States / NCI NIH HHS / CA / U01 CA111275; United States / NCI NIH HHS / CA / P50CA69568; United States / NCI NIH HHS / CA / U01 CA111275-01
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 5' Untranslated Regions; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / ERG protein, human; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / TMPRSS2-ERG fusion protein, human; 0 / Trans-Activators; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / TMPRSS2 protein, human; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ PMC1715928
  •  go-up   go-down


34. Hardie C, Parker C, Norman A, Eeles R, Horwich A, Huddart R, Dearnaley D: Early outcomes of active surveillance for localized prostate cancer. BJU Int; 2005 May;95(7):956-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early outcomes of active surveillance for localized prostate cancer.
  • OBJECTIVE: To describe the preliminary clinical outcomes of active surveillance (AS), a new strategy aiming to individualize the management of early prostate cancer by selecting only those men with significant cancers for curative therapy, and illustrate the contrast with a policy of watchful waiting (WW).
  • PATIENTS AND METHODS: Eighty men with early prostate cancer began AS at the authors' institution between 1993 and 2002.
  • Eligibility included histologically confirmed prostatic adenocarcinoma, fitness for radical treatment, clinical stage T1/T2, N0/X, M0/X, a prostate specific antigen (PSA) level of < or = 20 ng/mL, and a Gleason score of < or = 7.
  • During the same period, 32 men with localized prostate cancer (any T stage, N0/X, M0/X, any PSA, Gleason score < or = 7) were managed by WW; hormonal treatment was indicated for symptomatic prostate cancer progression.
  • No patient developed evidence of metastatic disease, none started palliative hormone therapy, and there were no deaths from prostate cancer.
  • Of the 11 patients who received radical treatment all remained biochemically controlled with no clinical evidence of recurrent disease.
  • Twenty (62%) of the 32 patients on WW remained on observation, eight (25%) received palliative hormonal therapy and four (12%) died, including one from prostate cancer.
  • CONCLUSIONS: AS is feasible in selected men with early prostate cancer.
  • [MeSH-major] Adenocarcinoma / therapy. Prostatic Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / therapeutic use. Clinical Protocols. Disease-Free Survival. Feasibility Studies. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Prostate-Specific Antigen / blood. Prostatectomy / methods

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15839912.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


35. Nemoto K, Tomita Y: Neuroendocrine differentiation of localized prostate cancer during endocrine therapy. Scand J Urol Nephrol; 2007;41(6):558-60
Hazardous Substances Data Bank. BICALUTAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine differentiation of localized prostate cancer during endocrine therapy.
  • A 74-year-old male was treated with endocrine therapy for localized prostate cancer.
  • After 25 months he complained of a swollen neck, and was diagnosed with prostate cancer with lymph node metastasis of neuroendocrine differentiation.
  • Neuroendocrine differentiation without elevation of conventional tumor markers is rare during the initial recurrent course of localized prostate cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Anilides / therapeutic use. Cell Differentiation / drug effects. Goserelin / therapeutic use. Nitriles / therapeutic use. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / pathology. Tosyl Compounds / therapeutic use
  • [MeSH-minor] Aged. Antineoplastic Agents, Hormonal / pharmacology. Antineoplastic Agents, Hormonal / therapeutic use. Humans. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local / diagnosis. Prostate-Specific Antigen / blood

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. GOSERELIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17853028.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Anilides; 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Tosyl Compounds; 0F65R8P09N / Goserelin; A0Z3NAU9DP / bicalutamide; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


36. Han B, Mehra R, Suleman K, Tomlins SA, Wang L, Singhal N, Linetzky KA, Palanisamy N, Zhou M, Chinnaiyan AM, Shah RB: Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod Pathol; 2009 Sep;22(9):1176-85
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma.
  • Histologic variants of prostate carcinoma account for 5-10% of the disease and are typically seen in association with conventional acinar carcinoma.
  • Recently, recurrent gene fusions between the androgen-regulated gene TMPRSS2 and the ETS transcription factors ERG, ETV1, ETV4, or ETV5 have been identified in a majority of conventional prostate carcinomas.
  • However, the frequency and significance of this critical molecular event is unknown in the histologic variants of prostate carcinoma.
  • Here, we used break-apart fluorescence in situ hybridization to assess TMPRSS2 and ETS aberrations in a series of select histologic variants: foamy gland carcinoma (N=17), ductal adenocarcinoma (N=18), mucinous carcinoma (N=18), and small cell carcinoma (N=7).
  • A histologic variation of acinar adenocarcinoma, demonstrating glomeruloid morphology (N=9), was also investigated.
  • TMPRSS2:ERG fusion was identified in 83% (15/18), 71% (5/7), 50% (9/18), 33% (3/9), and 29% (5/17) of mucinous, small cell, ductal, glomeruloid, and foamy gland prostate carcinomas, respectively.
  • Previously, we reported that 100% of androgen-independent metastatic prostate carcinomas harboring TMPRSS2:ERG gene fusion were associated with interstitial deletion (Edel).
  • SPINK1, a biomarker expressed exclusively in a subset of ETS negative prostate carcinomas, was expressed in 6% of ETS negative histologic variants, specifically in ductal adenocarcinoma.
  • Overall, our data provide insight into the origin, molecular mechanism, and phenotypic association of ETS fusions in histologic variants of prostate carcinoma.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res. 1999;1(1):31-5 [11250680.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8337-41 [16951139.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jun;40(2):152-7 [15101049.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):316-27 [14976541.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2375-84 [8839828.001]
  • [Cites] Mod Pathol. 1997 Jun;10(6):612-29 [9195581.001]
  • [Cites] Int J Exp Pathol. 2005 Aug;86(4):213-8 [16045543.001]
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3396-400 [16585160.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10242-6 [17079440.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):41-51 [17173048.001]
  • [Cites] Neoplasia. 2007 Mar;9(3):200-6 [17401460.001]
  • [Cites] Mod Pathol. 2007 May;20(5):538-44 [17334343.001]
  • [Cites] J Pathol. 2007 May;212(1):91-101 [17385188.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):882-8 [17527075.001]
  • [Cites] J Clin Pathol. 2007 Jul;60(7):781-6 [16901974.001]
  • [Cites] Oncogene. 2007 Jul 5;26(31):4596-9 [17237811.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):595-9 [17671502.001]
  • [Cites] Mod Pathol. 2007 Sep;20(9):921-8 [17632455.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):7991-5 [17804708.001]
  • [Cites] J Clin Pathol. 2007 Nov;60(11):1238-43 [17259299.001]
  • [Cites] Urology. 2007 Oct;70(4):630-3 [17991527.001]
  • [Cites] Br J Cancer. 2007 Dec 17;97(12):1690-5 [17971772.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):73-80 [18172298.001]
  • [Cites] Oncogene. 2008 Jan 10;27(3):253-63 [17637754.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3094-8 [18451133.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3584-90 [18483239.001]
  • [Cites] Cancer Cell. 2008 Jun;13(6):519-28 [18538735.001]
  • [Cites] Cancer Res. 2008 Sep 15;68(18):7629-37 [18794152.001]
  • [Cites] Cancer Metastasis Rev. 2002;21(3-4):381-95 [12549773.001]
  • (PMID = 19465903.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA069568-110020; United States / NCI NIH HHS / CA / U01 CA111275-01; United States / NCI NIH HHS / CA / R01 CA102872; United States / NCI NIH HHS / CA / P50CA69568; United States / NCI NIH HHS / CA / CA069568-110020; United States / NCI NIH HHS / CA / UO1 CA111275-01; United States / NCI NIH HHS / CA / P50 CA069568; United States / NCI NIH HHS / CA / U01 CA111275
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins c-ets; 0 / SPINK1 protein, human; 0 / TMPRSS2-ERG fusion protein, human; 0 / TMPRSS2-ETV1 fusion protein, human
  • [Other-IDs] NLM/ NIHMS148618; NLM/ PMC2760291
  •  go-up   go-down


37. Zhang K, Aruva MR, Shanthly N, Cardi CA, Rattan S, Patel C, Kim C, McCue PA, Wickstrom E, Thakur ML: PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer. J Nucl Med; 2008 Jan;49(1):112-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer.
  • Among U.S. men, prostate cancer (PC) accounts for 29% of all newly diagnosed cancers.
  • A reliable scintigraphic agent to image PC and its metastatic or recurrent lesions and to determine the effectiveness of its treatment will contribute to the management of this disease.
  • Prostate histology served as the gold standard.
  • Organ distribution studies (percentage injected dose per gram [%ID/g]) in normal prostate were performed.
  • The ratios of tumor to muscle, tumor to blood, normal prostate to muscle, and tumor to normal prostate were determined.
  • The ratios of PC to normal prostate at 4 and 24 h were 4 and 2.7, respectively. (64)Cu-TP3939 distinctly imaged histologic grade IV prostate intraepithelial neoplasia in transgenic mice, but (18)F-FDG and CT did not.
  • It may also be useful for localizing recurrent lesions and for determining the effectiveness of its treatment.
  • [MeSH-major] Adenocarcinoma / metabolism. Prostatic Neoplasms / metabolism. Receptors, Vasoactive Intestinal Polypeptide, Type I / biosynthesis

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18077536.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 109231
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Copper Radioisotopes; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / Receptors, Vasoactive Intestinal Polypeptide, Type I; 37221-79-7 / Vasoactive Intestinal Peptide
  •  go-up   go-down


38. Fernandes LC, Kim SB, Saad SS, Matos D: Value of carcinoembryonic antigen and cytokeratins for the detection of recurrent disease following curative resection of colorectal cancer. World J Gastroenterol; 2006 Jun 28;12(24):3891-4
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of carcinoembryonic antigen and cytokeratins for the detection of recurrent disease following curative resection of colorectal cancer.
  • AIM: To evaluate the efficacy of postoperative serial assay of carcinoembryonic antigen (CEA) and cytokeratins for the detection of recurrent disease in patients with colorectal adenocarcinoma after radical surgery.
  • METHODS: Between 1993 and 2000, 120 patients with colorectal adenocarcinoma underwent radical surgery in the Department of Surgical Gastroenterology, Federal University of Sao Paulo-Escola Paulista de Medicina, Sao Paulo, Brazil.
  • RESULTS: In the first postoperative year, patients without recurrent disease had normal levels of CEA (1.5 +/- 0.9 microg/L) and monoclonal tissue polypeptide antigen-M (TPA-M, 64.4 +/- 47.8 U/L), while patients with recurrences had high levels of CEA (6.9 +/- 9.8 microg/L, P < 0.01) and TPA-M (192.2 +/- 328.8 U/L, P < 0.05).
  • [MeSH-major] Adenocarcinoma / blood. Carcinoembryonic Antigen / blood. Colorectal Neoplasms / blood. Keratins / blood. Neoplasm Recurrence, Local / blood. Neoplasm Recurrence, Local / diagnosis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2001 Feb;44(2):231-5 [11227940.001]
  • [Cites] Ann Surg Oncol. 2000 Jan-Feb;7(1):32-7 [10674446.001]
  • [Cites] Int J Biol Markers. 2003 Jul-Sep;18(3):182-7 [14535588.001]
  • [Cites] World J Gastroenterol. 2004 Jul 1;10(13):1890-2 [15222030.001]
  • [Cites] Cancer Detect Prev. 1983;6(1-2):41-50 [6883392.001]
  • [Cites] Cancer. 1985 Mar 15;55(6):1284-90 [3971297.001]
  • [Cites] Prostate. 1985;6(3):285-91 [3991370.001]
  • [Cites] Cancer. 1988 Jan 1;61(1):76-83 [2446734.001]
  • [Cites] Cancer. 1989 Dec 1;64(11):2354-60 [2804927.001]
  • [Cites] Cancer. 1990 Aug 15;66(4):722-32 [2167141.001]
  • [Cites] Minerva Urol Nefrol. 1990 Apr-Jun;42(2):69-71 [2392743.001]
  • [Cites] Eur J Cancer. 1990;26(5):577-80 [2144745.001]
  • [Cites] Ann Intern Med. 1991 Oct 15;115(8):623-38 [1716430.001]
  • [Cites] JAMA. 1993 Aug 25;270(8):943-7 [8141873.001]
  • [Cites] Int J Biol Markers. 1994 Oct-Dec;9(4):231-8 [7836801.001]
  • [Cites] Dis Colon Rectum. 1995 Jun;38(6):619-26 [7774474.001]
  • [Cites] Eur J Surg Oncol. 1995 Aug;21(4):388-90 [7664904.001]
  • [Cites] J Surg Oncol. 1996 Aug;62(4):239-44 [8691835.001]
  • [Cites] Br J Cancer. 1996 Sep;74(6):925-9 [8826859.001]
  • [Cites] Dis Colon Rectum. 1997 Feb;40(2):145-9 [9075747.001]
  • [Cites] Recent Results Cancer Res. 1998;146:48-55 [9670248.001]
  • [Cites] Dig Dis Sci. 1998 Jul;43(7):1434-42 [9690377.001]
  • [Cites] Br J Cancer. 1998 Nov;78(10):1379-84 [9823983.001]
  • [Cites] Dis Colon Rectum. 1999 Jul;42(7):921-9 [10411440.001]
  • [Cites] J Exp Med. 1965 Mar 1;121:439-62 [14270243.001]
  • [Cites] World J Gastroenterol. 2005 Feb 7;11(5):645-8 [15655814.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1865-78 [11251019.001]
  • (PMID = 16804977.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 68238-35-7 / Keratins
  • [Other-IDs] NLM/ PMC4087940
  •  go-up   go-down


39. Shikanov S, Shikanov A, Gofrit O, Nyska A, Corn B, Domb AJ: Intratumoral delivery of paclitaxel for treatment of orthotopic prostate cancer. J Pharm Sci; 2009 Mar;98(3):1005-14
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumoral delivery of paclitaxel for treatment of orthotopic prostate cancer.
  • Locally recurrent prostate cancer can lead to significant morbidity, metastasis, and even death.
  • The objective of this study was to evaluate the efficacy of an injectable polymeric paste formulation containing paclitaxel against orthotopic prostate tumor in rats.
  • The Dunning R-3327 rat prostate adenocarcinoma is experimental tumor model used to study tumor progression.
  • The polymer loaded with paclitaxel was injected into the tumor bearing prostate glands of the rats 3 days after tumor cell inoculation.
  • In control untreated rats, tumor volume reached 14 cm(3) after 25 days, while in rats treated with intratumoral injection of polymer/paclitaxel formulation the prostate volume with the tumor was only 0.9 cm(3), 35 days posttumor cells inoculation.
  • The results of this study indicated that a site-directed, injectable, controlled release formulation of paclitaxel is effective against localized prostate tumors and metastasis.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc. and the American Pharmacists Association
  • (PMID = 18661540.001).
  • [ISSN] 1520-6017
  • [Journal-full-title] Journal of pharmaceutical sciences
  • [ISO-abbreviation] J Pharm Sci
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Ointments; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


40. Opfermann KJ, Lai Z, Essenmacher L, Bolton S, Ager J, Forman JD: Intermittent hormone therapy in nonmetastatic prostate cancer. Clin Genitourin Cancer; 2006 Sep;5(2):138-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intermittent hormone therapy in nonmetastatic prostate cancer.
  • PURPOSE: The object of this study was to evaluate the duration of response to intermittent androgen deprivation (IAD) in patients with nonmetastatic recurrent or localized prostate cancer.
  • Patients were considered resistant to hormone therapy if the prostate-specific antigen (PSA) level increased, with castrate levels of testosterone.
  • [MeSH-major] Adenocarcinoma / drug therapy. Androgen Antagonists / therapeutic use. Gonadotropin-Releasing Hormone / therapeutic use. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17026802.001).
  • [ISSN] 1558-7673
  • [Journal-full-title] Clinical genitourinary cancer
  • [ISO-abbreviation] Clin Genitourin Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 33515-09-2 / Gonadotropin-Releasing Hormone; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


41. Waltering KK, Wallén MJ, Tammela TL, Vessella RL, Visakorpi T: Mutation screening of the androgen receptor promoter and untranslated regions in prostate cancer. Prostate; 2006 Nov 1;66(15):1585-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutation screening of the androgen receptor promoter and untranslated regions in prostate cancer.
  • BACKGROUND: Mechanisms, other than gene amplification, leading to overexpression of AR in androgen ablation-resistant prostate cancer remain unknown and could include genetic alterations in the promoter or untranslated regions (UTR) of the AR gene.
  • MATERIALS AND METHODS: DNAs from five prostate cancer cell lines, 19 LuCaP xenografts, 44 clinical tumors, and 36 non-malignant controls were used for screening mutations in the upstream regulatory region, promoter and the 5'- and 3'-UTRs of the AR gene with denaturating high performance liquid chromatography (DHPLC) and sequencing.
  • RESULTS: Ten different sequence variations were found in prostate cancer cell lines and xenografts.
  • However, none of them were recurrent or were found in clinical prostate cancer specimens or in normal controls.
  • CONCLUSIONS: Recurrent mutations in the promoter or UTRs of AR seem to be rare, and thus not likely mechanisms for the increased expression of the gene in the androgen ablation-resistant prostate cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Mutation. Promoter Regions, Genetic. Prostatic Neoplasms / genetics. Receptors, Androgen / genetics. Untranslated Regions

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16927275.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Neoplasm; 0 / Receptors, Androgen; 0 / Untranslated Regions
  •  go-up   go-down


42. Rubin MA, Chinnaiyan AM: Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer. Lab Invest; 2006 Nov;86(11):1099-102
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer.
  • Recurrent chromosomal rearrangements have not been well characterized in common carcinomas.
  • These novel gene fusions suggest a mechanism for overexpression of the ETS genes in the majority of prostate cancers identified through PSA screening.
  • Considering the high incidence of prostate cancer and the high frequency of this gene fusion, the TMPRSS2-ETS gene fusions are the most common genetic aberration so far described in human malignancies.
  • [MeSH-major] Adenocarcinoma / genetics. Computational Biology / methods. DNA-Binding Proteins / genetics. Gene Fusion. Oncogene Proteins, Fusion / genetics. Prostatic Neoplasms / genetics. Serine Endopeptidases / genetics. Transcription Factors / genetics

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16983328.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / ETV1 protein, human; 0 / Oncogene Proteins, Fusion; 0 / TMPRSS2-ETS fusion protein, human; 0 / Transcription Factors; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / TMPRSS2 protein, human
  •  go-up   go-down


43. Beinart G, Rini BI, Weinberg V, Small EJ: Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin Prostate Cancer; 2005 Jun;4(1):55-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer.
  • BACKGROUND: Antigen-presenting cells 8015 (APC8015; Provenge) is an immunotherapeutic product designed to initiate a T-cell-mediated immune response against prostatic acid phosphatase, an antigen overexpressed in 95% of prostate cancer cells.
  • In phase I/II trials, APC8015 has shown immunologic and clinical responses in patients with androgen-independent prostate cancer.
  • This phase II trial was conducted to assess the prostate-specific antigen (PSA)-modulating effects of APC8015 in patients with androgen-dependent prostate cancer (ADPC) with biochemical progression.
  • PATIENTS AND METHODS: Patients with nonmetastatic recurrent disease as manifested by increasing PSA levels (0.4-6.0 ng/mL) and who had undergone previous definitive surgical or radiation therapy were enrolled.
  • Prostate-specific antigen was measured at baseline and monthly until disease progression, defined as a doubling of the baseline or nadir PSA value (whichever was lower) to > or = 4 ng/mL or development of distant metastases.
  • [MeSH-major] Adenocarcinoma / immunology. Adenocarcinoma / therapy. Antigen-Presenting Cells. Immunotherapy / methods. Prostate-Specific Antigen / blood. Prostatic Neoplasms / immunology. Prostatic Neoplasms / therapy


44. Uemura H, Hasumi H, Kawahara T, Sugiura S, Miyoshi Y, Nakaigawa N, Teranishi J, Noguchi K, Ishiguro H, Kubota Y: Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int J Clin Oncol; 2005 Dec;10(6):405-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer.
  • BACKGROUND: We previously demonstrated that an angiotensin II receptor blocker (ARB) had the potential to inhibit cell proliferation of prostate cancer.
  • In this study, we examined whether an ARB could elicit an antiproliferative effect on hormone-refractory prostate cancer, clinically.
  • METHODS: Twenty-three patients with advanced hormone-refractory prostate cancer who had already received secondary hormonal therapy using dexamethasone, and who were no longer receiving conventional therapy, were enrolled.
  • Change in prostate-specific antigen (PSA) was determined as the primary endpoint.
  • To investigate angiotensin II type 1 (AT1) receptor expression in prostate cancer tissue, real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was performed, using specimens, from untreated patients with prostate cancer.
  • The RT-PCR showed that AT1 receptor expression in well-differentiated adenocarcinoma was higher than that in poorly differentiated adenocarcinoma.
  • CONCLUSION: These data showed that an ARB had potential biological effects on prostate cancer, suggesting the usefulness of the cytostatic activity of such agents on recurrent prostate cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Angiotensin II Type 1 Receptor Blockers / therapeutic use. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / therapeutic use. Benzimidazoles / administration & dosage. Benzimidazoles / therapeutic use. Drug Resistance, Neoplasm. Humans. Male. Middle Aged. Pilot Projects. Prostate-Specific Antigen / metabolism. RNA, Messenger / metabolism. Receptor, Angiotensin, Type 1 / genetics. Receptor, Angiotensin, Type 1 / metabolism. Tetrazoles / administration & dosage. Tetrazoles / therapeutic use

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. CANDESARTAN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16369744.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Angiotensin II Type 1 Receptor Blockers; 0 / Antineoplastic Agents, Hormonal; 0 / Benzimidazoles; 0 / RNA, Messenger; 0 / Receptor, Angiotensin, Type 1; 0 / Tetrazoles; EC 3.4.21.77 / Prostate-Specific Antigen; S8Q36MD2XX / candesartan
  •  go-up   go-down


45. Woodle ES, Gupta M, Buell JF, Neff GW, Gross TG, First MR, Hanaway MJ, Trofe J: Prostate cancer prior to solid organ transplantation: the Israel Penn International Transplant Tumor Registry experience. Transplant Proc; 2005 Mar;37(2):958-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer prior to solid organ transplantation: the Israel Penn International Transplant Tumor Registry experience.
  • INTRODUCTION: Prostate adenocarcinoma (PCA) is the second leading cause of cancer-related deaths in men, and with routine prostrate specific antigen (PSA) screening, is being diagnosed with increasing frequency.
  • Median time to PCA recurrence was 10.6 months after transplantation and median survival time with recurrent PCA was 49.2 months after transplant.
  • [MeSH-major] Adenocarcinoma / complications. Heart Transplantation. Kidney Transplantation. Liver Transplantation. Prostatic Neoplasms / complications


46. Heebøll S, Borre M, Ottosen PD, Andersen CL, Mansilla F, Dyrskjøt L, Orntoft TF, Tørring N: SMARCC1 expression is upregulated in prostate cancer and positively correlated with tumour recurrence and dedifferentiation. Histol Histopathol; 2008 09;23(9):1069-76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SMARCC1 expression is upregulated in prostate cancer and positively correlated with tumour recurrence and dedifferentiation.
  • BACKGROUND: The identification of new prognostic markers in prostate cancer (PC) is essential to improve patient treatment and management.
  • MATERIALS: Expression of SMARCC1 immunostaining was analysed on a tissue microarray containing specimens from 327 patients with prostate cancer and clinical follow-up information.
  • Furthermore, 30 specimens from patients with benign prostate hyperplasia were included as controls as well as 30 specimens of benign prostate tissue from PC patients.
  • In contrast, 20% of the specimens from patients with non-metastatic and non-recurrent disease showed moderate to marked staining.
  • In 31% of the patients with recurrent disease and in 31% of the patients with metastatic disease we found moderate to strong SMARCC1 immunostaining.
  • In a logistic regression analysis, patients with a marked SMARCC1 immunostaining had a significantly elevated odds ratio (OR) of 16 for recurrent cancer and an OR of 4.5 for metastatic disease.
  • Conclusions. Our present results demonstrate an increased expression of SMARCC1 protein in prostate cancer and reveal a positive correlation with tumour dedifferentiation, progression, metastasis and time to recurrence.
  • [MeSH-major] Adenocarcinoma / metabolism. Prostatic Neoplasms / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Animals. Biomarkers, Tumor / metabolism. COS Cells. Cell Dedifferentiation. Cell Nucleus / metabolism. Cell Nucleus / pathology. Cercopithecus aethiops. Fluorescent Antibody Technique, Direct. Humans. Immunoenzyme Techniques. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local. Odds Ratio. Prostate / metabolism. Prostate / pathology. Prostatic Hyperplasia / metabolism. Prostatic Hyperplasia / pathology. Tissue Array Analysis. Up-Regulation

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18581278.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SMARCC1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


47. Wetherill YB, Fisher NL, Staubach A, Danielsen M, de Vere White RW, Knudsen KE: Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status. Cancer Res; 2005 Jan 1;65(1):54-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status.
  • Androgen is critical for prostate development, growth, and survival.
  • Therapies for advanced prostate cancer aim to block androgen receptor (AR) action.
  • However, recurrent tumors ultimately arise, which harbor restored AR activity.
  • We have shown previously that a known xenoestrogen, bisphenol A (BPA), activates a tumor-derived AR mutant (T877A), leading to androgen-independent prostate cancer cell proliferation.
  • Here, we show that BPA cooperates with androgen to activate AR-T877A as shown by both reporter assays and increased levels of prostate-specific antigen expression.
  • Further investigations using both yeast and mammalian model systems revealed that multiple AR alleles are responsive to BPA, thus expanding the potential influence of xenoestrogens on prostate cancer.
  • We also show that higher concentrations of BPA block proliferation of AR-positive, androgen-dependent prostate adenocarcinoma cells (LNCaP and LAPC-4), with a more modest inhibitory effect on androgen-independent cells (22Rv-1).
  • By contrast, AR-negative prostate cancer cells failed to show growth inhibition after exposure to high BPA dose.
  • Together, these data show that BPA can serve as a potential "hormone sensitizer" of the mutant ARs present in advanced prostate adenocarcinomas, thereby possibly contributing toward therapeutic relapse in advanced prostate cancer patients and supporting the notion that nonsteroidal environmental compounds can alter the function of nuclear receptor complexes.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BISPHENOL A DISODIUM SALT .
  • Hazardous Substances Data Bank. BISPHENOL A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15665279.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / E30-ES--06096; United States / NIEHS NIH HHS / ES / ES-07250-16; United States / NCI NIH HHS / CA / R01-CA 093404-03
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzhydryl Compounds; 0 / Estrogens, Non-Steroidal; 0 / Phenols; 0 / Receptors, Androgen; 08J2K08A3Y / Dihydrotestosterone; EC 1.13.12.- / Luciferases; MLT3645I99 / bisphenol A
  •  go-up   go-down


48. Hasumi H, Ishiguro H, Nakamura M, Sugiura S, Osada Y, Miyoshi Y, Fujinami K, Yao M, Hamada K, Yamada-Okabe H, Kubota Y, Uemura H: Neuroserpin (PI-12) is upregulated in high-grade prostate cancer and is associated with survival. Int J Cancer; 2005 Jul 20;115(6):911-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroserpin (PI-12) is upregulated in high-grade prostate cancer and is associated with survival.
  • We carried out Genechip analysis using prostate cancer and non-malignant tissue to identify specific genes related to prostate cancer.
  • We focused on neuroserpin (PI-12), which has been identified as one of the genes with high expression in prostate cancer.
  • Prostate cancer and normal prostate tissue were analyzed by Affymetrix GeneChip technology.
  • We carried out real-time quantitative PCR on a total of 102 specimens: 45 of normal prostate, 45 of previously untreated prostate cancer (constituting 45 pairs of samples obtained at radical prostatectomy, with each pair dissected from the same prostate specimen) and 12 of recurrent hormone refractory prostate cancer (HRPC).
  • Results showed that the neuroserpin gene was more highly expressed in prostate cancer than in normal prostate tissue.
  • Neuroserpin expression in untreated prostate cancer was significantly higher than that in normal prostate.
  • In HRPC it was significantly higher than that in untreated prostate cancer and normal prostate.
  • In untreated prostate cancer, neuroserpin expression was significantly higher in high grade tumors such as poorly differentiated adenocarcinoma than in lower grade tumors such as well or moderately differentiated adenocarcinoma.
  • The neuroserpin gene may be associated with the development, progression and aggressiveness of prostate cancer.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15723353.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neuropeptides; 0 / Serpins; 0 / neuroserpin
  •  go-up   go-down


49. Huss WJ, Gray DR, Greenberg NM, Mohler JL, Smith GJ: Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. Cancer Res; 2005 Aug 1;65(15):6640-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells.
  • Malignantly transformed stem cells represent a potential common nidus for the primary cancer and the recurrent cancer that arises after treatment failure.
  • Putative prostate stem cells and prostate tumor stem cells in benign and malignant human prostate tissue, in primary human prostate xenografts, and in the transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse model of prostate cancer, are defined by expression of breast cancer resistance protein (BCRP), a marker of pluripotent hematopoietic, muscle, and neural stem cells, and by an absence of androgen receptor (AR) protein.
  • Inhibition of BCRP-mediated efflux of dihydrotestosterone by novobiocin or fumitremorgin C in a rat prostate progenitor cell line that expresses BCRP and AR mRNAs, but minimal AR protein, results in stabilization and nuclear translocation of AR protein, providing a mechanism for lack of AR protein in BCRP-expressing stem cells.
  • In both benign and malignant human prostate tissue, the rare epithelial cells that express BCRP and lack AR protein are localized in the basal cell compartment, survive androgen deprivation, and maintain proliferative potential in the hypoxic, androgen-deprived prostate.
  • Putative prostate tumor stem cells that express BCRP but not AR protein in TRAMP are the source of a BCRP-negative and AR-negative, Foxa2- and SV40Tag-expressing, transit amplifying compartment that progresses to the poorly differentiated carcinomas that arise rapidly after castration.
  • Therefore, BCRP expression isolates prostate stem/tumor stem cells from the prostate tissue microenvironment through constitutive efflux of androgen, protecting the putative tumor stem cells from androgen deprivation, hypoxia, or adjuvant chemotherapy, and providing the nidus for recurrent prostate cancer.

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NOVOBIOCIN .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061644.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA84296; United States / NCI NIH HHS / CA / P01 CA077739; United States / NCI NIH HHS / CA / CA77739; United States / NCI NIH HHS / CA / CA64851; United States / NIEHS NIH HHS / ES / ES07017; United States / NCI NIH HHS / CA / CA64865
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / Androgens; 0 / Indoles; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Receptors, Androgen; 17EC19951N / Novobiocin; CW5S8OP3VO / tryptoquivaline
  •  go-up   go-down


50. Rouzier C, Haudebourg J, Carpentier X, Valério L, Amiel J, Michiels JF, Pedeutour F: Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data. Cancer Genet Cytogenet; 2008 May;183(1):21-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data.
  • The recent identification of fusion genes involving ETS family members in human prostate adenocarcinoma has confirmed the hypothesis that recurrent specific aberrations such as fusion genes may be as frequent in epithelial tumors as they are in leukemias and sarcomas.
  • We retrospectively analyzed a large series of formalin-fixed, paraffin-embedded samples including 55 prostate carcinomas and 11 benign prostate tumors.
  • No significant association between the presence of the fusion gene and any clinical feature, such as preoperative serum prostate-specific antigen (PSA) level (PSA>20 or PSA< or =20), pTNM stage including capsule invasion, seminal vesicle invasion, and lymph nodes metastases, or recurrence was observed in our series.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Paraffin Embedding. Prostatic Neoplasms / genetics. Prostatic Neoplasms / pathology. Proto-Oncogene Proteins c-ets / analysis. Serine Endopeptidases / analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Elsevier Inc.
  • (PMID = 18474293.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenovirus E1A Proteins; 0 / DNA-Binding Proteins; 0 / ETV1 protein, human; 0 / ETV4 protein, human; 0 / Fixatives; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-ets; 0 / TMPRSS2-ERG fusion protein, human; 0 / TMPRSS2-ETS fusion protein, human; 0 / TMPRSS2-ETV1 fusion protein, human; 0 / TMPRSS2-ETV4 fusion protein, human; 0 / Transcription Factors; 1HG84L3525 / Formaldehyde; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / TMPRSS2 protein, human
  •  go-up   go-down


51. Bruchovsky N, Klotz L, Crook J, Phillips N, Abersbach J, Goldenberg SL: Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer. Clin Genitourin Cancer; 2008 Mar;6(1):46-52
MedlinePlus Health Information. consumer health - Prostate Cancer Screening.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer.
  • BACKGROUND: Observations of quality of life (QOL), morbidity, and mortality were obtained from the results of a prospective phase II study of intermittent androgen suppression for recurrent prostate cancer after radiation therapy.
  • PATIENTS AND METHODS: Patients with histologically confirmed adenocarcinoma of the prostate and a rising serum prostate-specific antigen level after external-beam radiation of the prostate were treated intermittently with a 36-week course of cyproterone and leuprolide.
  • CONCLUSION: Intermittent androgen suppression is a potentially useful treatment for locally recurrent prostate cancer after radiation therapy with QOL benefits in the off-treatment interval and no apparent deleterious effects on short- to medium-term survival.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Prostate-Specific Antigen / blood. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / mortality. Quality of Life
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / radiotherapy. Aged. Humans. Male. Morbidity. Prospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18501083.001).
  • [ISSN] 1558-7673
  • [Journal-full-title] Clinical genitourinary cancer
  • [ISO-abbreviation] Clin Genitourin Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


52. Bruchovsky N, Klotz L, Crook J, Goldenberg SL: Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. Cancer; 2007 Mar 1;109(5):858-67
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
  • BACKGROUND: Biochemical results from a prospective Phase II trial of intermittent androgen suppression for recurrent prostate cancer after radiotherapy were analyzed for correlations to the onset of hormone-refractory disease.
  • METHODS: Patients with histologically confirmed adenocarcinoma of the prostate and a rising serum prostate-specific antigen (PSA) level after external beam irradiation of the prostate were treated intermittently with a 36-week course of cyproterone acetate and leuprolide acetate.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Prostate-Specific Antigen / blood. Prostatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • Hazardous Substances Data Bank. CYPROTERONE ACETATE .
  • Hazardous Substances Data Bank. LEUPROLIDE .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer. 2007 Jul 15;110(2):467-8; author reply 468 [17559131.001]
  • (PMID = 17265527.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; 3XMK78S47O / Testosterone; 4KM2BN5JHF / Cyproterone Acetate; EC 3.4.21.77 / Prostate-Specific Antigen; EFY6W0M8TG / Leuprolide
  •  go-up   go-down


53. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA: TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol; 2007 Jun;31(6):882-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.
  • Prostate cancer (PCA) is one of the most prevalent cancers and a major leading cause of morbidity and mortality in the Western world.
  • The TMPRSS2-ERG fusion was recently identified as a common recurrent chromosomal aberration in this malignancy.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Neoplasm Invasiveness / genetics. Oncogene Proteins, Fusion / genetics. Prostatic Neoplasms / genetics. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2008 Apr;32(4):642-4; author reply 644 [18317354.001]
  • (PMID = 17527075.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA090381; United States / NCI NIH HHS / CA / P50CA58236; United States / NCI NIH HHS / CA / P50CA89520; United States / NIA NIH HHS / AG / R01AG21404
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / TMPRSS2-ERG fusion protein, human
  •  go-up   go-down


54. van Weert HC, Pingen F: Recurrent thromboflebitis as a warning sign for cancer: a case report. Cases J; 2009;2:153

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent thromboflebitis as a warning sign for cancer: a case report.
  • When screened for underlying causes a renal cell carcinoma and an adenocarcinoma of the prostate are diagnosed.
  • CONCLUSION: Unprovoked and recurrent thrombophlebitis is a rare condition and its presentation might be a warning sign for a (yet undiagnosed) cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1992 May 1;69(9):2267-70 [1562972.001]
  • [Cites] Am J Med. 1995 Dec;99(6):662-71 [7503090.001]
  • [Cites] Am J Med Sci. 1995 Mar;309(3):183-7 [7879824.001]
  • [Cites] Ann Intern Med. 2008 Sep 2;149(5):323-33 [18765702.001]
  • [Cites] Angiology. 2003 Jan;54(1):11-7 [12593491.001]
  • [Cites] J Fam Pract. 2006 Jan;55(1):52-7 [16388768.001]
  • [Cites] Blood. 2007 Sep 15;110(6):1723-9 [17496204.001]
  • [Cites] Gastroenterology. 1994 Aug;107(2):537-42 [8039630.001]
  • (PMID = 19946524.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2783109
  •  go-up   go-down


55. Knudsen KE, Scher HI: Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res; 2009 Aug 1;15(15):4792-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.
  • Clinical data and models of human disease indicate that androgen receptor (AR) activity is essential for prostate cancer development, growth, and progression.
  • The dependence of prostatic adenocarcinoma on AR signaling at all stages of disease has thereby been exploited in the treatment of disseminated tumors, for which ablation of AR function is the goal of first-line therapy.
  • Although these strategies are initially effective, recurrent tumors arise with restored AR activity, and no durable treatment has yet been identified to combat this stage of disease.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BICALUTAMIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Endocrinol Metab. 2009 Jan;20(1):43-50 [19008119.001]
  • [Cites] Clin Cancer Res. 2009 Jan 1;15(1):39-47 [19118031.001]
  • [Cites] Nat Clin Pract Urol. 2009 Feb;6(2):76-85 [19198621.001]
  • [Cites] Oncogene. 2009 Feb 19;28(7):1016-27 [19079343.001]
  • [Cites] Clin Cancer Res. 2009 Mar 15;15(6):2091-7 [19276271.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1665-71 [16551847.001]
  • [Cites] Urol Int. 2006;77(2):135-8 [16888418.001]
  • [Cites] J Cell Biochem. 2006 Oct 1;99(2):373-81 [16598769.001]
  • [Cites] Cancer Cell. 2006 Oct;10(4):309-19 [17045208.001]
  • [Cites] Urology. 2006 Oct;68(4):834-9 [17070363.001]
  • [Cites] J Urol. 2006 Dec;176(6 Pt 2):S66-71 [17084172.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11998-2008 [17178899.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):719-33 [17163421.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Curr Med Chem. 2000 Feb;7(2):211-47 [10637363.001]
  • [Cites] Endocr J. 1999 Oct;46(5):659-64 [10670751.001]
  • [Cites] J Med Chem. 2001 Feb 1;44(3):453-67 [11462984.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):34-45 [11900250.001]
  • [Cites] Mol Cell. 2002 Mar;9(3):601-10 [11931767.001]
  • [Cites] Semin Oncol. 2003 Oct;30(5):709-16 [14571418.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):217-27 [14695335.001]
  • [Cites] Nat Med. 2004 Jan;10(1):33-9 [14702632.001]
  • [Cites] Br J Cancer. 2004 Jun 14;90(12):2317-25 [15150570.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2927-41 [15184404.001]
  • [Cites] Agents Actions. 1988 Dec;25(3-4):307-13 [2464275.001]
  • [Cites] J Steroid Biochem Mol Biol. 1994 Sep;50(5-6):267-73 [7918112.001]
  • [Cites] Cell. 2006 Feb 10;124(3):615-29 [16469706.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2815-25 [16510604.001]
  • [Cites] Mol Cancer Ther. 2007 Jan;6(1):51-60 [17218635.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1331-6 [17227854.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Apr;4(4):236-44 [17392714.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1596-605 [17404365.001]
  • [Cites] Mol Endocrinol. 2007 Dec;21(12):2855-63 [17636035.001]
  • [Cites] Mol Cell Endocrinol. 2008 Jan 16;281(1-2):1-8 [18060684.001]
  • [Cites] Nucl Recept Signal. 2008;6:e001 [18301781.001]
  • [Cites] Adv Exp Med Biol. 2008;617:245-55 [18497048.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4447-54 [18519708.001]
  • [Cites] Urology. 2008 Jun;71(6):1001-6 [18407326.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):2959-65 [18565882.001]
  • [Cites] Cancer Res. 2008 Jul 1;68(13):5469-77 [18593950.001]
  • [Cites] Urol Oncol. 2008 Jul-Aug;26(4):415-9 [18593620.001]
  • [Cites] Nucl Recept Signal. 2008;6:e008 [18612376.001]
  • [Cites] Expert Opin Pharmacother. 2008 Aug;9(11):1969-79 [18627334.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6407-15 [18676866.001]
  • [Cites] Mol Cancer Ther. 2008 Aug;7(8):2348-57 [18723482.001]
  • [Cites] Nat Clin Pract Urol. 2008 Sep;5(9):486-93 [18769375.001]
  • [Cites] Eur Urol. 2008 Oct;54(4):805-13 [18538469.001]
  • [Cites] Curr Cancer Drug Targets. 2008 Sep;8(6):490-7 [18781895.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4563-71 [18645193.001]
  • [Cites] Curr Opin Pharmacol. 2008 Aug;8(4):440-8 [18674639.001]
  • [Cites] Mol Cancer Ther. 2008 Oct;7(10):3187-94 [18852122.001]
  • [Cites] Mol Cancer Ther. 2008 Oct;7(10):3195-202 [18852123.001]
  • [Cites] J Urol. 2008 Nov;180(5):1986-92 [18801505.001]
  • [Cites] Mol Endocrinol. 2008 Nov;22(11):2373-82 [18617596.001]
  • [Cites] Nat Clin Pract Urol. 2008 Nov;5(11):610-20 [18985049.001]
  • [Cites] Endocr Relat Cancer. 2008 Dec;15(4):841-9 [18667687.001]
  • [Cites] Urol Oncol. 2009 Jan-Feb;27(1):36-41 [19111796.001]
  • [Cites] Urol Oncol. 2009 Jan-Feb;27(1):67-71 [19111801.001]
  • [Cites] Cancer Res. 2009 Jan 1;69(1):16-22 [19117982.001]
  • [Cites] Cancer Res. 2009 Feb 1;69(3):958-66 [19176386.001]
  • (PMID = 19638458.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / R01 ES016675-10; United States / NCI NIH HHS / CA / CA116777-04; United States / NIEHS NIH HHS / ES / ES016675-10; United States / NCI NIH HHS / CA / R01 CA099996; United States / NCI NIH HHS / CA / R01 CA116777-04; United States / NCI NIH HHS / CA / CA099996-07A2; United States / NCI NIH HHS / CA / R01 CA099996-07A2; United States / NCI NIH HHS / CA / R01 CA116777; United States / NIEHS NIH HHS / ES / R01 ES016675
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AR protein, human; 0 / Androgen Antagonists; 0 / Androgen Receptor Antagonists; 0 / Androgens; 0 / Anilides; 0 / Nitriles; 0 / Receptors, Androgen; 0 / Tosyl Compounds; 76W6J0943E / Flutamide; A0Z3NAU9DP / bicalutamide
  • [Number-of-references] 62
  • [Other-IDs] NLM/ NIHMS120367; NLM/ PMC2842118
  •  go-up   go-down


56. Block T, Czempiel H, Zimmermann F: Transperineal permanent seed implantation of "low-risk" prostate cancer: 5-year-experiences in 118 patients. Strahlenther Onkol; 2006 Nov;182(11):666-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transperineal permanent seed implantation of "low-risk" prostate cancer: 5-year-experiences in 118 patients.
  • PURPOSE: To evaluate 5-year prostate-specific antigen (PSA) relapse-free survival of transperineal permanent seed implantation (TPSI) in 118 patients with "low-risk" prostate cancer, that means stage cT1c-T2a, Gleason Score < 7, and initial PSA value < 10 ng/ml.
  • Out of the six patients with recurrent disease, three had a local tumor recurrence only, and three developed distant metastases.
  • CONCLUSION: In low-risk prostate cancer patients, TPSI with intraoperative ultrasound-based treatment planning and fluoroscopy leads to excellent local tumor control and PSA relapse-free survival.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Iodine Radioisotopes / administration & dosage. Prostatic Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Biopsy. Cohort Studies. Disease-Free Survival. Fluoroscopy. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Prostate / pathology. Prostate-Specific Antigen / blood. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Risk Factors. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17072525.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


57. Wetherill YB, Hess-Wilson JK, Comstock CE, Shah SA, Buncher CR, Sallans L, Limbach PA, Schwemberger S, Babcock GF, Knudsen KE: Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer. Mol Cancer Ther; 2006 Dec;5(12):3181-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer.
  • Clinical evidence has shown that androgen receptor is reactivated in recurrent tumors despite the continuance of androgen deprivation therapy.
  • Moreover, we have shown that BPA can promote cell cycle progression in cultured prostate cancer cells under conditions of androgen deprivation.
  • Here, we challenged the effect of BPA on the therapeutic response in a xenograft model system of prostate cancer containing the endogenous BPA-responsive AR-T877A mutant protein.
  • These effects were mediated, at least in part, through androgen receptor activity, as prostate-specific antigen levels rose with accelerated kinetics in BPA-exposed animals.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BISPHENOL A DISODIUM SALT .
  • Hazardous Substances Data Bank. BISPHENOL A .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17172422.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / S10 RR019900-01; United States / NIEHS NIH HHS / ES / E30-ES-06096; United States / NCRR NIH HHS / RR / RR019900-01; United States / NCI NIH HHS / CA / R01-CA 093404; United States / NCRR NIH HHS / RR / RR019900; United States / NCRR NIH HHS / RR / S10 RR019900; United States / NIEHS NIH HHS / ES / ES-07250-16
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Receptor Antagonists; 0 / Androgens; 0 / Benzhydryl Compounds; 0 / Phenols; MLT3645I99 / bisphenol A
  •  go-up   go-down


58. Mimeault M, Johansson SL, Henichart JP, Depreux P, Batra SK: Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells. Mol Cancer Ther; 2010 Mar;9(3):617-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells.
  • The present study has been undertaken to establish the therapeutic benefit of cotargeting epidermal growth factor receptor (EGFR) and sonic hedgehog pathways by using gefitinib and cyclopamine, respectively, for improving the efficacy of the current chemotherapeutic drug docetaxel to counteract the prostate cancer progression from locally invasive to metastatic and recurrent disease stages.
  • The data from immuofluorescence analyses revealed that EGFR/Tyr(1173)-pEGFR, sonic hedgehog ligand, smoothened coreceptor, and GLI-1 were colocalized with the CD133(+) stem cell-like marker in a small subpopulation of prostate cancer cells.
  • These signaling molecules were also present in the bulk tumor mass of CD133(-) prostate cancer cells with a luminal phenotype detected in patient's adenocarcinoma tissues.
  • Altogether, these observations suggest that EGFR and sonic hedgehog cascades may represent the potential therapeutic targets of great clinical interest to eradicate the total prostate cancer cell mass and improve the current docetaxel-based therapies against locally advanced and invasive prostate cancers, and thereby prevent metastases and disease relapse.
  • [MeSH-major] Adenocarcinoma / pathology. Prostate / drug effects. Prostate / pathology. Prostatic Neoplasms / pathology. Quinazolines / pharmacology. Taxoids / pharmacology. Veratrum Alkaloids / pharmacology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocrinology. 2004 Aug;145(8):3961-70 [15132968.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4807-15 [17510410.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1502-12 [15470213.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1513-20 [15470214.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] Am J Respir Cell Mol Biol. 1992 Dec;7(6):574-81 [1449805.001]
  • [Cites] Hum Pathol. 1998 Sep;29(9):1005-12 [9744319.001]
  • [Cites] Mol Cancer. 2004 Oct 13;3:29 [15482598.001]
  • [Cites] Int J Cancer. 2005 Feb 10;113(4):619-28 [15472903.001]
  • [Cites] Prostate. 2005 Feb 1;62(2):187-99 [15389789.001]
  • [Cites] J Pathol. 2005 Mar;205(4):522-9 [15685688.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):2990-2 [15833820.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Carcinogenesis. 2006 Jan;27(1):1-22 [16195239.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):1022-31 [16108016.001]
  • [Cites] Oncogene. 2006 Mar 16;25(12):1696-708 [16449977.001]
  • [Cites] Cell Mol Life Sci. 2006 Feb;63(4):435-48 [16389455.001]
  • [Cites] Endocr Relat Cancer. 2006 Mar;13(1):197-210 [16601288.001]
  • [Cites] J Urol. 2006 Aug;176(2):532-7 [16813883.001]
  • [Cites] Prostate. 2006 Sep 15;66(13):1437-44 [16741920.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):160-9 [17013895.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):967-78 [17363490.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3153-61 [17409422.001]
  • [Cites] Lab Invest. 2000 Aug;80(8):1243-50 [10950115.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4885-92 [11156248.001]
  • [Cites] Bioorg Med Chem Lett. 2001 Jul 23;11(14):1911-4 [11459659.001]
  • [Cites] J Cell Sci. 2001 Nov;114(Pt 21):3865-72 [11719553.001]
  • [Cites] J Pathol. 2001 Dec;195(5):563-70 [11745692.001]
  • [Cites] Int J Oncol. 2002 Apr;20(4):681-9 [11894110.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1253-64 [12006546.001]
  • [Cites] J Immunol Methods. 2002 Jul 1;265(1-2):39-47 [12072177.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3438-44 [12429632.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3870-6 [12473602.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Mar;129(3):165-74 [12712332.001]
  • [Cites] Cytometry A. 2003 Aug;54(2):89-99 [12879455.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Br J Cancer. 2004 Jan 26;90(2):449-54 [14735192.001]
  • [Cites] Pancreas. 2004 May;28(4):401-12 [15097858.001]
  • [Cites] J Cell Sci. 2004 Jul 15;117(Pt 16):3539-45 [15226377.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jun 15;357(4):1084-9 [17466949.001]
  • [Cites] Cancer. 2007 Jun 1;109(11):2239-47 [17455209.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6796-805 [17638891.001]
  • [Cites] Prostate. 2007 Sep 15;67(13):1384-96 [17639507.001]
  • [Cites] J Urol. 2007 Sep;178(3 Pt 2):S30-5 [17644121.001]
  • [Cites] Cancer Lett. 2007 Oct 8;255(2):300-6 [17602833.001]
  • [Cites] Cancer Biol Ther. 2007 May;6(5):763-8 [17592251.001]
  • [Cites] Ernst Schering Found Symp Proc. 2006;(5):155-79 [17939301.001]
  • [Cites] J Cell Mol Med. 2007 Sep-Oct;11(5):981-1011 [17979879.001]
  • [Cites] Mo Med. 2007 Sep-Oct;104(5):408-13; quiz 413-4 [18018527.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Growth Factors. 2007 Dec;25(6):400-16 [18365871.001]
  • [Cites] Endocr Rev. 2008 Apr;29(2):234-52 [18292464.001]
  • [Cites] Prostate. 2008 Jun 15;68(9):1007-24 [18398820.001]
  • [Cites] J Cell Physiol. 2008 Sep;216(3):571-5 [18481259.001]
  • [Cites] Genome Biol. 2008;9(5):R83 [18492237.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7905-14 [18829547.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):268-73 [19116269.001]
  • [Cites] Ageing Res Rev. 2009 Apr;8(2):94-112 [19114129.001]
  • [Cites] Cancer Genomics Proteomics. 2008 Nov-Dec;5(6):301-10 [19287071.001]
  • [Cites] Clin Exp Metastasis. 2009;26(5):433-46 [19221883.001]
  • [Cites] Methods Mol Biol. 2009;568:139-49 [19582424.001]
  • [Cites] Stem Cells Dev. 2009 Dec;18(10):1515-22 [19260804.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6 [15314219.001]
  • (PMID = 20179163.001).
  • [ISSN] 1538-8514
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA138791; United States / NCI NIH HHS / CA / R01 CA138791-03
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytotoxins; 0 / GLI1 protein, human; 0 / Quinazolines; 0 / Taxoids; 0 / Transcription Factors; 0 / Veratrum Alkaloids; 15H5577CQD / docetaxel; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib; ZH658AJ192 / cyclopamine
  • [Other-IDs] NLM/ NIHMS173400; NLM/ PMC3228252
  •  go-up   go-down


59. Watson SK, Woolcock BW, Fee JN, Bainbridge TC, Webber D, Kinahan TJ, Lam WL, Vielkind JR: Minimum altered regions in early prostate cancer progression identified by high resolution whole genome tiling path BAC array comparative hybridization. Prostate; 2009 Jun 15;69(9):961-75
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimum altered regions in early prostate cancer progression identified by high resolution whole genome tiling path BAC array comparative hybridization.
  • BACKGROUND: Carcinoma of the prostate (CaP) is a serious health problem.
  • RESULTS: Our comprehensive aCGH approach allowed us to define 35 regions of recurrent alterations while excluding germline copy number polymorphisms.
  • [MeSH-major] Adenocarcinoma / genetics. Comparative Genomic Hybridization. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Prostatic Neoplasms / genetics
  • [MeSH-minor] Chromosome Breakage. Chromosomes, Artificial, Bacterial. Chromosomes, Human. Disease Progression. Epithelial Cells / physiology. Gene Dosage. Genomics / methods. Humans. Male. Microdissection. Polymorphism, Genetic. Prostate / pathology. Prostate / physiology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19267368.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


60. Yamada T, Ohtsubo K, Mouri H, Yamashita K, Yasumoto K, Izumi K, Zen Y, Watanabe H, Yano S: Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis. Int J Clin Oncol; 2009 Oct;14(5):468-72
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined chemotherapy with carboplatin plus irinotecan showed favorable efficacy in a patient with relapsed small cell carcinoma of the prostate complicated with meningeal carcinomatosis.
  • We report the case of a 65-year-old man with recurrent prostate cancer who presented with meningeal carcinomatosis.
  • In September 2007, he had been diagnosed with mixed type small cell carcinoma and adenocarcinoma at clinical stage T4N1M1 (primary prostate tumor with multiple bone, liver, and lymph node metastases) and hormonal therapy had been administered.
  • Small cell carcinoma of the prostate complicated with meningeal carcinomatosis was diagnosed.
  • In conclusion, we report the efficacy of combined treatment with carboplatin plus irinotecan for small cell carcinoma of the prostate complicated with meningeal carcinomatosis.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19856060.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Peptide Fragments; 0 / Recombinant Proteins; 0 / pro-gastrin-releasing peptide (31-98); 7673326042 / irinotecan; BG3F62OND5 / Carboplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


61. Chaplin BJ, Wildhagen MF, Schroder FH, Kirkels WJ, Bangma CH: Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up. Eur Urol; 2005 Dec;48(6):906-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.
  • OBJECTIVES: We determined the role of Digital Rectal Examination (DRE) in the follow-up of those patients treated with radical prostatectomy for clinically localised prostate cancer having an undetectable PSA.
  • A strict definition of PSA progression was used, that is any elevation above undetectable PSA or lowest recorded post-operative PSA (nadir), in order not to miss a single patient who may have recurrent local disease or distant metastases without PSA progression.
  • We counted local recurrent disease as those patients having histologically proven adenocarcinoma on TRUS directed biopsies, and distant disease as those patients having detectable metastatic disease on radionuclide bone scan.
  • [MeSH-major] Digital Rectal Examination / utilization. Neoplasm Recurrence, Local / diagnosis. Prostate-Specific Antigen / blood. Prostatectomy / methods. Prostatic Neoplasms / diagnosis. Unnecessary Procedures

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16126322.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


62. De Cicco L, Vavassori A, Cattani F, Jereczek-Fossa BA, Orecchia R: Salvage high dose rate brachytherapy after primary external beam irradiation in localized prostate cancer: a case report. Tumori; 2009 Jul-Aug;95(4):553-6
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage high dose rate brachytherapy after primary external beam irradiation in localized prostate cancer: a case report.
  • No standard treatment exists for locally relapsed prostate cancer after primary external beam radiotherapy with no evidence of distant metastases.
  • We report on a patient who has no evidence of disease and no late urinary or gastrointestinal toxicity 33 months after receiving HDR treatment for recurrent prostate cancer.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Neoplasm Recurrence, Local / radiotherapy. Prostatic Neoplasms / radiotherapy. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Tumori. 2010 May-Jun;96(3):512; author reply 512-3 [20845820.001]
  • (PMID = 19856677.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


63. Thomas-Kaskel AK, Veelken H: [Active immunotherapy of prostate cancer with a focus on dendritic cells]. Actas Urol Esp; 2007 Jun;31(6):668-79
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Active immunotherapy of prostate cancer with a focus on dendritic cells].
  • [Transliterated title] Inmunoterapia activa en cáncer de próstata: revisión con atención especial a las células dendríticas.
  • Recurrent or metastatic prostate cancer is generally considered an incurable disease.
  • Prostate cancer cells express several tumor associated antigens which are currently being evaluated as targets for active and specific immunotherapy approaches.
  • Close to 1000 prostate cancer patients have been treated with DC-based or other forms of active immunotherapy to date.
  • [MeSH-major] Adenocarcinoma / therapy. Cancer Vaccines / therapeutic use. Dendritic Cells / transplantation. Immunotherapy, Active. Prostatic Neoplasms / therapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17896564.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / Vaccines, Synthetic
  • [Number-of-references] 95
  •  go-up   go-down


64. Ryan CJ, Haqq CM, Simko J, Nonaka DF, Chan JM, Weinberg V, Small EJ, Goldfine ID: Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer. Urol Oncol; 2007 Mar-Apr;25(2):134-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer.
  • PURPOSE: The insulin-like growth factor (IGF)-1 receptor is currently being targeted in clinical trials in prostate cancer.
  • MATERIALS AND METHODS: Immunohistochemistry was used to determine the presence of IGF-1 receptor in frozen normal prostate and prostate cancer specimens.
  • RESULTS: IGF-1 receptor was expressed in normal prostate epithelium in 6 of 6 patients without cancer and in morphologically normal epithelium adjacent to tumor cells in 21 of 22 patients with cancer studied.
  • IGF-1 receptor was present in the prostate tumor epithelium of 28 of 28 primary tumors, 3 of 5 locally recurrent androgen-independent tumors, and in 4 of 5 metastatic lymph nodes.
  • CONCLUSIONS: This study using frozen tissue shows widespread IGF-1 receptor expression in normal prostate, prostate cancers, and metastases.
  • These data support investigations into IGF-1 receptor as a therapeutic target in prostate cancer.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Aged. Aged, 80 and over. Biomarkers, Tumor. Epithelium / metabolism. Epithelium / pathology. Humans. Lymph Nodes. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis. Prostate / metabolism. Prostate / pathology. Receptor, Insulin / metabolism. Receptors, Androgen / metabolism. Stromal Cells / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17349528.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA115775-01; United States / NCI NIH HHS / CA / P50 CA89520; United States / NCI NIH HHS / CA / R01 CA101042-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Androgen; EC 2.7.10.1 / Receptor, IGF Type 1; EC 2.7.10.1 / Receptor, Insulin
  •  go-up   go-down


65. Sridhar SS, Hotte SJ, Chin JL, Hudes GR, Gregg R, Trachtenberg J, Wang L, Tran-Thanh D, Pham NA, Tsao MS, Hedley D, Dancey JE, Moore MJ: A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. Am J Clin Oncol; 2010 Dec;33(6):609-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer.
  • Since EGFR and HER2 overexpression has also been seen in prostate cancer and appears to correlate with a worse clinical outcome, Lapatinib may represent a novel therapeutic strategy in prostate cancer.
  • This Phase II multicenter clinical trial is the first to evaluate Lapatinib in early stage, hormonally untreated recurrent or metastatic prostate cancer.
  • The primary end point was prostate specific antigen (PSA) response.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Neoplasm Recurrence, Local / pathology. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / pathology. Quinazolines / therapeutic use
  • [MeSH-minor] Administration, Oral. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Dose-Response Relationship, Drug. Drug Administration Schedule. Follow-Up Studies. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Prostate-Specific Antigen / blood. Risk Assessment. Single-Blind Method. Survival Rate. Treatment Outcome


66. Hess-Wilson JK, Webb SL, Daly HK, Leung YK, Boldison J, Comstock CE, Sartor MA, Ho SM, Knudsen KE: Unique bisphenol A transcriptome in prostate cancer: novel effects on ERbeta expression that correspond to androgen receptor mutation status. Environ Health Perspect; 2007 Nov;115(11):1646-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unique bisphenol A transcriptome in prostate cancer: novel effects on ERbeta expression that correspond to androgen receptor mutation status.
  • Recurrent tumors ultimately arise wherein AR has been re-activated.
  • In tumors with specific AR mutations, BPA promotes therapeutic bypass, suggesting significant negative impact to the clinical management of prostate cancer.
  • METHODS: The molecular signature of BPA activity in prostate cancer cells harboring mutant AR was delineated via genetic microarray analysis.
  • RESULTS: BPA and DHT elicited distinct transcriptional signatures in prostate cancer cells expressing the BPA-responsive mutant AR-T877A.
  • BPA dramatically attenuated estrogen receptor beta (ERbeta) expression; this finding was specific to prostate tumor cells in which BPA induces cellular proliferation.
  • CONCLUSIONS: BPA induces a distinct gene expression signature in prostate cancer cells expressing somatic AR mutation, and a major molecular consequence of BPA action is down-regulation of ERbeta.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BISPHENOL A DISODIUM SALT .
  • Hazardous Substances Data Bank. BISPHENOL A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Endocrinol. 2007 Jan 15;263(1-2):46-54 [17023111.001]
  • [Cites] Mol Cancer Ther. 2006 Dec;5(12):3181-90 [17172422.001]
  • [Cites] Endocrinology. 2007 Feb;148(2):566-74 [17068134.001]
  • [Cites] PLoS Genet. 2007 Jan 12;3(1):e5 [17222059.001]
  • [Cites] Oncogene. 2007 Nov 15;26(52):7346-54 [17525739.001]
  • [Cites] Environ Health Perspect. 2003 Jun;111(8):994-1006 [12826473.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2673-8 [12860943.001]
  • [Cites] Cancer Invest. 2003 Jun;21(3):400-17 [12901287.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Oct 3;309(4):937-45 [13679064.001]
  • [Cites] Genome Biol. 2003;4(10):R70 [14519205.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):6056-62 [14522935.001]
  • [Cites] Int J Oncol. 2004 Feb;24(2):399-407 [14719117.001]
  • [Cites] Neoplasia. 2004 Mar-Apr;6(2):179-85 [15140407.001]
  • [Cites] Biotechniques. 2004 May;36(5):790-6 [15152598.001]
  • [Cites] Am J Pathol. 2004 Jun;164(6):2003-12 [15161636.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9375-80 [15187231.001]
  • [Cites] J Clin Pathol. 2004 Aug;57(8):872-6 [15280411.001]
  • [Cites] Urology. 2004 Oct;64(4):814-20 [15491740.001]
  • [Cites] Biochem Biophys Res Commun. 1990 Dec 14;173(2):534-40 [2260966.001]
  • [Cites] Biochemistry. 1992 Mar 3;31(8):2393-9 [1540595.001]
  • [Cites] J Steroid Biochem Mol Biol. 1992 Mar;41(3-8):665-9 [1562539.001]
  • [Cites] Endocr Rev. 1993 Oct;14(5):577-93 [8262007.001]
  • [Cites] J Steroid Biochem Mol Biol. 1993 Dec;46(6):759-65 [8274409.001]
  • [Cites] Cancer Res. 1994 Oct 15;54(20):5474-8 [7522959.001]
  • [Cites] Endocrinology. 1995 Feb;136(2):796-803 [7530653.001]
  • [Cites] Prog Clin Biol Res. 1996;394:3-23 [8778803.001]
  • [Cites] Invest New Drugs. 1999;17(3):271-84 [10665479.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):944-9 [10706109.001]
  • [Cites] Nat Med. 2000 Jun;6(6):703-6 [10835690.001]
  • [Cites] Cancer Res. 2000 Jun 15;60(12):3175-82 [10866308.001]
  • [Cites] Cancer. 2000 Jun 15;88(12 Suppl):3009-14 [10898345.001]
  • [Cites] J Biol Chem. 2000 Aug 25;275(34):26164-71 [10840043.001]
  • [Cites] EMBO J. 2000 Oct 16;19(20):5406-17 [11032808.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 22;98(11):6330-5 [11371645.001]
  • [Cites] Mol Cell Endocrinol. 2001 Jun 10;178(1-2):47-50 [11403893.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):79-92 [11438457.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5331-5 [11454669.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):34-45 [11900250.001]
  • [Cites] Science. 2002 Mar 29;295(5564):2465-8 [11923541.001]
  • [Cites] Prostate. 2002 Jun 1;52(1):69-81 [11992621.001]
  • [Cites] Mol Cell Endocrinol. 2002 Jul 31;193(1-2):1-5 [12160995.001]
  • [Cites] J Steroid Biochem Mol Biol. 2002 Jul;81(3):191-201 [12163131.001]
  • [Cites] Genome Biol. 2002 Jun 25;3(7):RESEARCH0036 [12184810.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):32510-5 [12084714.001]
  • [Cites] Mol Cancer Ther. 2002 May;1(7):515-24 [12479269.001]
  • [Cites] Oncogene. 2002 Dec 12;21(57):8749-58 [12483528.001]
  • [Cites] Cell Mol Life Sci. 2003 Mar;60(3):567-76 [12737316.001]
  • [Cites] Pharmacol Toxicol. 2003 Apr;92(4):180-8 [12753421.001]
  • [Cites] Pathol Res Pract. 1996 Jul;192(7):752-60 [8880876.001]
  • [Cites] Endocrinology. 1997 Mar;138(3):863-70 [9048584.001]
  • [Cites] Endocrinology. 1998 Oct;139(10):4252-63 [9751507.001]
  • [Cites] Nat Med. 1999 Mar;5(3):280-5 [10086382.001]
  • [Cites] Mol Cell Endocrinol. 2005 Jan 14;229(1-2):103-10 [15607534.001]
  • [Cites] N Engl J Med. 2004 Dec 23;351(26):2773-4 [15616218.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2005 Mar;288(3):E573-84 [15536203.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):584-93 [15701844.001]
  • [Cites] Endocrinology. 2006 Jan;147(1):590-8 [16210365.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):54-65 [15665279.001]
  • [Cites] Environ Health Perspect. 2005 Apr;113(4):391-5 [15811827.001]
  • [Cites] Environ Res. 2006 Jan;100(1):86-92 [16029874.001]
  • [Cites] Breast Cancer Res Treat. 2006 Apr;96(3):279-92 [16328721.001]
  • [Cites] Endocrinology. 2006 Jun;147(6 Suppl):S25-32 [16690802.001]
  • [Cites] Endocrinology. 2006 Jun;147(6 Suppl):S56-69 [16690810.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 8;103(32):12033-8 [16882715.001]
  • [Cites] Mol Aspects Med. 2006 Aug;27(4):299-402 [16914190.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13162-7 [16938840.001]
  • [Cites] J Cell Biochem. 2006 Oct 1;99(2):333-44 [16518832.001]
  • [Cites] Cancer Lett. 2006 Oct 28;242(2):222-30 [16458425.001]
  • [Cites] Neoplasia. 2006 Nov;8(11):896-904 [17132221.001]
  • (PMID = 18007998.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / T32 ES007250; United States / NCI NIH HHS / CA / CA099996; United States / NIEHS NIH HHS / ES / ES016675-07; United States / NCI NIH HHS / CA / T32 CA117846; United States / NIEHS NIH HHS / ES / E30-ES-06096; United States / NIEHS NIH HHS / ES / ES93404; United States / NIEHS NIH HHS / ES / P30 ES006096; United States / NIEHS NIH HHS / ES / R01 ES016675-07; United States / NCI NIH HHS / CA / R01 CA099996; United States / NIEHS NIH HHS / ES / ES-07250-16; United States / NIEHS NIH HHS / ES / R01 ES016675
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzhydryl Compounds; 0 / Estrogen Receptor beta; 0 / Estrogens, Non-Steroidal; 0 / Phenols; 0 / Receptors, Androgen; 08J2K08A3Y / Dihydrotestosterone; MLT3645I99 / bisphenol A
  • [Other-IDs] NLM/ PMC2072856
  • [Keywords] NOTNLM ; androgen receptor / endocrine disruptor / microarray / prostatic adenocarcinoma / xeno-estrogen
  •  go-up   go-down


67. Scheble VJ, Braun M, Beroukhim R, Mermel CH, Ruiz C, Wilbertz T, Stiedl AC, Petersen K, Reischl M, Kuefer R, Schilling D, Fend F, Kristiansen G, Meyerson M, Rubin MA, Bubendorf L, Perner S: ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol; 2010 Aug;23(8):1061-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor.
  • The recently discovered recurrent ERG rearrangement in prostate cancer might represent a prostate cancer-specific alteration that has not been systematically assessed in tumors other than prostate cancer.
  • Aim of this study was to assess, whether the ERG rearrangement and the distinct deletion site between TMPRSS2 and ERG, both predominantly resulting in a TMPRSS2-ERG fusion, occur in tumors other than prostate cancer.
  • To calibrate, we analyzed 285 prostate cancer samples for the ERG rearrangement frequency.
  • None of the 54 different tumor types assessed by FISH harbored an ERG rearrangement, whereas the prostate cancer samples revealed an ERG rearrangement in 49.5% of cases.
  • Furthermore, within the 26 tumor types assessed for copy number alterations by SNP, the distinct deletion site between TMPRSS2 and ERG (21q22.2-3) was detectable exclusively in prostate cancer.
  • Although Ewing's sarcoma and AML have known rearrangements rarely involving ERG, we hypothesize that the ERG rearrangement as well as the distinct deletion site on 21q22.2-3 between TMPRSS2 and ERG are prostate-cancer-specific genomic alterations.
  • These observations provide further insight into the oncogenesis of prostate cancer and might be critical for the development of ERG rearrangement assessment as a clinical tool.
  • [MeSH-major] Adenocarcinoma / genetics. Gene Rearrangement. Prostatic Neoplasms / genetics. Trans-Activators / genetics

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2008 Sep 11;27(40):5348-53 [18542058.001]
  • [Cites] Oncogene. 2008 Mar 27;27(14):1993-2003 [17922029.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Oct;8(10):1675-87 [18925858.001]
  • [Cites] Clin Cancer Res. 2009 Jul 15;15(14):4706-11 [19584163.001]
  • [Cites] Nat Rev Urol. 2009 Aug;6(8):429-39 [19657377.001]
  • [Cites] Eur Urol. 2009 Aug;56(2):275-86 [19409690.001]
  • [Cites] Science. 2009 Oct 9;326(5950):289-93 [19815776.001]
  • [Cites] Science. 2009 Nov 27;326(5957):1230 [19933109.001]
  • [Cites] Nature. 2010 Feb 18;463(7283):899-905 [20164920.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Sep;44(1):103-8 [15887243.001]
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):717-9 [16575875.001]
  • [Cites] Neoplasia. 2006 Jun;8(6):465-9 [16820092.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8337-41 [16951139.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8347-51 [16951141.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Nov;45(11):1018-32 [16897747.001]
  • [Cites] Neoplasia. 2006 Oct;8(10):826-32 [17032499.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10242-6 [17079440.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):233-45 [17361217.001]
  • [Cites] Crit Rev Oncog. 2006 Dec;12(3-4):257-71 [17425505.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):882-8 [17527075.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):7991-5 [17804708.001]
  • [Cites] Br J Cancer. 2007 Dec 17;97(12):1690-5 [17971772.001]
  • [Cites] Neoplasia. 2008 Mar;10(3):298-302 [18320074.001]
  • [Cites] Cancer Res. 2008 Oct 15;68(20):8516-24 [18922926.001]
  • (PMID = 20473283.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K08 CA122833; United States / NIGMS NIH HHS / GM / T32 GM007753
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / ERG protein, human; 0 / Oncogene Proteins, Fusion; 0 / TMPRSS2-ERG fusion protein, human; 0 / Trans-Activators; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / TMPRSS2 protein, human
  • [Other-IDs] NLM/ NIHMS432161; NLM/ PMC3606550
  •  go-up   go-down


68. Yasuda M, Shimizu M, Fujita M, Miyazawa M, Tang X, Kajiwara H, Osamura RY, Shoji S, Tokunaga M, Terachi T: Usefulness of hypoxia inducible factor-1 alpha in evaluating the prostatic adenocarcinoma viability following neoadjuvant hormone therapy. Cancer Detect Prev; 2007;31(5):396-401
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of hypoxia inducible factor-1 alpha in evaluating the prostatic adenocarcinoma viability following neoadjuvant hormone therapy.
  • HIF-1 alpha expression profiles were as follows: recurrent cases, weak, 19% (4/21); strong, 81% (17/21) (p<0.05); and non-recurrent cases, weak, 41% (12/29); strong, 59% (17/29) (NS).
  • [MeSH-major] Adenocarcinoma / drug therapy. Biomarkers, Tumor / analysis. Hormone Antagonists / therapeutic use. Hypoxia-Inducible Factor 1 / biosynthesis. Neoplasm Recurrence, Local / metabolism. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents. Cell Survival / drug effects. Humans. Immunohistochemistry. Male. Neoadjuvant Therapy. Prostate-Specific Antigen / blood

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18031949.001).
  • [ISSN] 1525-1500
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Hormone Antagonists; 0 / Hypoxia-Inducible Factor 1; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


69. García JR, Soler M, Blanch MA, Ramírez I, Riera E, Lozano P, Pérez X, Delgado E, Carrio I, Lomeña F: [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer]. Rev Esp Med Nucl; 2009 May-Jun;28(3):95-100
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
  • [Transliterated title] PET/TAC con (11)C-colina y (18)F-FDG en pacientes con elevación de PSA tras tratamiento radical de un cáncer de próstata.
  • OBJECTIVE: To compare the diagnostic accuracy of PET/CT with (18)F-FDG and (11)C-choline for early detection and localization of recurrent prostate cancer.
  • MATERIAL AND METHODS: Thirty-eight patients with increased PSA levels (0.8-9.5 ng/ml) after radical treatment for prostate cancer (surgery n = 20/radiation therapy n = 18) were included.
  • CONCLUSIONS: (11)C-choline PET/CT was useful for the detection of biochemical recurrence of prostate cancer, with higher yielding as compared to (18)F-FDG. (11)C-choline sensitivity was clearly related to PSA levels, was higher in patients with surgery and did not seem to be modified by hormonal therapy.
  • [MeSH-major] Adenocarcinoma / radiography. Adenocarcinoma / radionuclide imaging. Carbon Radioisotopes. Choline. Fluorine Radioisotopes. Fluorodeoxyglucose F18. Positron-Emission Tomography. Prostate-Specific Antigen / blood. Prostatic Neoplasms / radiography. Prostatic Neoplasms / radionuclide imaging. Radiopharmaceuticals. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19558948.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; 0 / Carbon Radioisotopes; 0 / Fluorine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; EC 3.4.21.77 / Prostate-Specific Antigen; N91BDP6H0X / Choline
  •  go-up   go-down


70. Sung MT, Jiang Z, Montironi R, MacLennan GT, Mazzucchelli R, Cheng L: Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy. Hum Pathol; 2007 Feb;38(2):332-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
  • Alpha-methylacyl-CoA racemase (AMACR) has recently been shown to be a highly sensitive marker for the diagnosis of prostate cancer.
  • However, there is limited information concerning its utility as a marker for prostate carcinoma after hormonal therapy.
  • Our current investigation was conducted to evaluate the expression of AMACR in patients with prostate carcinoma after hormonal therapy and assess its diagnostic utility in combination with p63 and high molecular weight cytokeratin (34betaE12) staining.
  • Prostate tissues from 49 patients who had been treated with hormonal therapy were immunohistochemically analyzed for AMACR, 34betaE12, and p63 expression by a triple antibody cocktail stain.
  • alpha-methylacyl-CoA racemase expression may be substantially diminished or entirely lost in prostate carcinoma after hormonal therapy.
  • It is important that pathologists be aware that some hormonally treated prostate carcinomas do not express AMACR, and that immunostaining in such cases must be interpreted with caution.
  • A triple cocktail stain using AMACR, 34betaE12, and p63 can be helpful in evaluating prostate specimens for the presence of residual or recurrent carcinoma after hormonal therapy for cancer.
  • [MeSH-major] Adenocarcinoma / pathology. DNA-Binding Proteins / analysis. Keratins / analysis. Prostatic Neoplasms / pathology. Racemases and Epimerases / analysis. Trans-Activators / analysis. Tumor Suppressor Proteins / analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17134736.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / CK-34 beta E12; 0 / DNA-Binding Proteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 68238-35-7 / Keratins; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


71. Spivey KA, Banyard J, Solis LM, Wistuba II, Barletta JA, Gandhi L, Feldman HA, Rodig SJ, Chirieac LR, Zetter BR: Collagen XXIII: a potential biomarker for the detection of primary and recurrent non-small cell lung cancer. Cancer Epidemiol Biomarkers Prev; 2010 May;19(5):1362-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collagen XXIII: a potential biomarker for the detection of primary and recurrent non-small cell lung cancer.
  • BACKGROUND: Collagen XXIII is a transmembrane collagen previously shown to be upregulated in metastatic prostate cancer.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 AACR
  • [Cites] Ann Intern Med. 2004 May 4;140(9):740-53 [15126259.001]
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):20989-94 [12644459.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5361-6 [15328173.001]
  • [Cites] Br J Cancer. 1997;75(10):1509-14 [9166946.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1395-9 [9537238.001]
  • [Cites] Lancet. 1999 Jun 5;353(9168):1930-3 [10371572.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):257-62 [16231326.001]
  • [Cites] Oncology (Williston Park). 2005 Nov;19(13):1724-30; discussion 1730-1 [16425524.001]
  • [Cites] J Biol Chem. 2006 Jul 28;281(30):21546-57 [16728390.001]
  • [Cites] Oncology. 2006;70(3):203-11 [16809939.001]
  • [Cites] Lung Cancer. 2006 Oct;54(1):87-94 [16876904.001]
  • [Cites] Ai Zheng. 2006 Nov;25(11):1361-7 [17094902.001]
  • [Cites] Nat Rev Cancer. 2007 Mar;7(3):169-81 [17318210.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2634-42 [17473194.001]
  • [Cites] Curr Opin Pulm Med. 2007 Jul;13(4):284-9 [17534174.001]
  • [Cites] J Biol Chem. 2007 Sep 14;282(37):27424-35 [17627939.001]
  • [Cites] Chest. 2007 Sep;132(3 Suppl):1S-19S [17873156.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):778-90 [17882278.001]
  • [Cites] Biomed Pharmacother. 2007 Oct;61(9):515-9 [17913444.001]
  • [Cites] Annu Rev Pathol. 2006;1:331-48 [18039118.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5578-83 [18065730.001]
  • [Cites] Histol Histopathol. 2008 Jun;23(6):693-700 [18366007.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):548-52 [18385728.001]
  • [Cites] Lancet Oncol. 2008 Jul;9(7):676-82 [18598932.001]
  • [Cites] Lung Cancer. 2009 Feb;63(2):164-8 [18599152.001]
  • [Cites] Diagn Cytopathol. 2009 Mar;37(3):178-83 [19170169.001]
  • [Cites] Cancer Res. 2009 Apr 1;69(7):2990-5 [19318550.001]
  • [Cites] Proc Am Thorac Soc. 2009 Apr 15;6(2):201-5 [19349489.001]
  • [Cites] Mod Pathol. 2009 Aug;22(8):1032-43 [19430419.001]
  • [Cites] Carcinogenesis. 2009 Nov;30(11):1903-9 [19736307.001]
  • [Cites] J Cell Mol Med. 2009 Aug;13(8B):1977-86 [19040416.001]
  • [Cites] Cancer. 2000 Dec 1;89(11 Suppl):2468-73 [11147629.001]
  • [Cites] Am J Clin Pathol. 2001 Dec;116(6):823-30 [11764070.001]
  • [Cites] EMBO J. 2002 Apr 2;21(7):1524-34 [11927537.001]
  • [Cites] Acta Odontol Latinoam. 2002;15(1-2):29-37 [15208940.001]
  • (PMID = 20447926.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA090578; United States / NCI NIH HHS / CA / R01 CA092824; United States / NCI NIH HHS / CA / CA070907-129004; United States / NCI NIH HHS / CA / P20 CA090578-05; United States / NCI NIH HHS / CA / CA092824; United States / NCI NIH HHS / CA / R01 CA074386; United States / NCI NIH HHS / CA / P50CA70907; United States / NCI NIH HHS / CA / R01 CA092824-07; United States / NCI NIH HHS / CA / CA074386; United States / NCI NIH HHS / CA / CA90578; United States / NCI NIH HHS / CA / P50 CA070907-129004; United States / NCI NIH HHS / CA / P50 CA090578; United States / NCI NIH HHS / CA / CA090578-05; United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / CA092824-07; United States / NCI NIH HHS / CA / R01 CA074386-11
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / COL23A1 protein, human; 9007-34-5 / Collagen
  • [Other-IDs] NLM/ NIHMS186813; NLM/ PMC2880394
  •  go-up   go-down


72. Tamsel S, Killi R, Apaydin E, Hekimgil M, Demirpolat G: The potential value of power Doppler ultrasound imaging compared with grey-scale ultrasound findings in the diagnosis of local recurrence after radical prostatectomy. Clin Radiol; 2006 Apr;61(4):325-30; discussion 323-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Eighteen patients were evaluated in whom local recurrence of prostate cancer was suspected on the basis of elevated serum prostate-specific antigen (PSA) levels (above 0.4 ng/ml) after RRP with no evidence of metastatic disease.
  • The ability to detect locally recurrent prostate cancer using grey-scale TRUS alone was compared with TRUS combined with PDUS.
  • RESULTS: Fifteen of the 18 patients (83%) had positive biopsies for local recurrent tumour at histological examination.
  • The sensitivity and specificity of TRUS alone in detecting recurrent tumour were 93 and 67%, respectively, with a positive predictive value (PPV) of 93% and a negative predictive value (NPV) of 67%.
  • [MeSH-major] Adenocarcinoma / ultrasonography. Neoplasm Recurrence, Local / ultrasonography. Prostatic Neoplasms / ultrasonography
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Biopsy / methods. Epidemiologic Methods. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood. Prostatectomy. Ultrasonography, Doppler. Ultrasonography, Doppler, Color. Ultrasonography, Interventional / methods

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16546462.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


73. Wu I, Jones JS: Intraprostatic abscess as a complication of salvage cryotherapy. Urology; 2010 Oct;76(4):848
MedlinePlus Health Information. consumer health - Abscess.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present a case of prostatic abscess as a previously unreported complication of salvage cryoablation after initial external beam radiotherapy for prostate cancer.
  • An 81-years-old gentleman presented with recurrent urinary tract infection, unresolved after repeated antibiotic treatments, and severe abdominal, back, and perineal pain that developed 2 weeks after undergoing cryotherapy at an outside institution.
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Aged, 80 and over. Anti-Bacterial Agents / therapeutic use. Combined Modality Therapy. Drainage. Humans. Male. Necrosis. Pain / etiology. Prostate / pathology. Prostatic Neoplasms / radiotherapy. Prostatic Neoplasms / surgery. Radiation Injuries / complications. Radiation Injuries / pathology. Radiotherapy / adverse effects. Urinary Tract Infections / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19963256.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


74. Gacci M, Serni S, Lapini A, Vittori G, Vignolini G, Nesi G, Carini M: PSA recurrence after brachytherapy for seed misplacement: a double-blind radiologic and pathologic work-up after salvage prostatectomy. Prostate Cancer Prostatic Dis; 2008;11(1):99-101
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 64-year-old man was treated with brachytherapy for prostate cancer.
  • Prostate-specific antigen (PSA) nadir was achieved at 3 months, while at 24 months PSA increased to 18.7 ng ml(-1).
  • Re-biopsy and imaging revealed locally recurrent prostate carcinoma without metastasis.
  • Radiology revealed an area without any seeds in the right base of the prostate, and pathologic assessment demonstrated adenocarcinoma involving the right base of the gland.
  • [MeSH-major] Brachytherapy / instrumentation. Neoplasm Recurrence, Local / blood. Prostate-Specific Antigen / blood. Prostatectomy. Prostatic Neoplasms / radiotherapy. Prostatic Neoplasms / surgery


75. Kim K, Cho YM, Hong YO, Kim SA, Ro JY: Bacillus calmette-guerin granuloma in seminal vesicle: report of the first case in the english literature. Int J Clin Exp Pathol; 2009;2(6):599-601

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 64-year-old man underwent a radical cystoprostatectomy for intravesical bacillus Calmette-Guerin (BCG) therapy-resistant, recurrent muscle invasive transitional cell carcinoma (TCC) of the urinary bladder.
  • On microscopic examination, not only multifocal residual papillary TCCs in the urinary bladder but also multiple small granulomas in the urinary bladder and prostate were noted.
  • Neither prostatic adenocarcinoma nor TCC involvement was identified in the prostate and seminal vesicles.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 1992 Apr;39(4):364-7 [1557848.001]
  • [Cites] Hinyokika Kiyo. 1991 Oct;37(10):1329-32 [1755428.001]
  • [Cites] Urol Int. 1991;46(1):99-100 [2024386.001]
  • [Cites] J Urol. 2003 Apr;169(4):1472 [12629388.001]
  • [Cites] Acta Cytol. 1989 Jan-Feb;33(1):1-5 [2916356.001]
  • [Cites] J Urol. 1986 Feb;135(2):272-4 [3511286.001]
  • [Cites] J Urol. 1976 Aug;116(2):180-3 [820877.001]
  • [Cites] J Urol. 1988 Oct;140(4):751-4 [3418796.001]
  • (PMID = 19636407.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2713449
  • [Keywords] NOTNLM ; BCG / Bacillus Calmette-Guerin / granuloma / seminal vesicles
  •  go-up   go-down


76. Vijan SS, Wall JC, Greenlee SM, Farley DR: Consequences of endoscopic inguinal hernioplasty with mesh on subsequent open radical prostatectomy. Hernia; 2008 Aug;12(4):415-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Case controls (n = 26) were matched for age, type of operation, year of surgery and pathologic stage of prostatic adenocarcinoma.
  • CONCLUSIONS: Prior TEP/TAPP did not increase the morbidity or mortality of subsequent prostate surgery.
  • While endoscopic hernia repair remains an excellent option to fix unilateral, bilateral, and recurrent herniae, consideration of future prostate surgery is important.
  • Inserting less "inflammatory" mesh or using an open, anterior approach may be prudent in some men at high risk for needing subsequent prostate surgery.
  • [MeSH-minor] Adenocarcinoma / surgery. Aged. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379718.001).
  • [ISSN] 1265-4906
  • [Journal-full-title] Hernia : the journal of hernias and abdominal wall surgery
  • [ISO-abbreviation] Hernia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] France
  •  go-up   go-down


77. Jamal K, Challacombe B, Elhage O, Popert R, Kirby R, Dasgupta P: Successful salvage robotic-assisted radical prostatectomy after external beam radiotherapy failure. Urology; 2008 Dec;72(6):1356-8
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 50-year-old man initially underwent combined external beam radiotherapy and hormonal treatment for Stage T2a prostate adenocarcinoma.
  • The prostate-specific antigen level was 10.5 ng/mL, and the Gleason score was 3+3.
  • Two years later, he developed biopsy-proven recurrent disease.
  • His prostate-specific antigen at 3 months was <0.03 ng/mL, and he was continent.
  • Salvage robotic-assisted radical prostatectomy is a safe and technically feasible salvage treatment for prostate cancer for which primary radiotherapy has failed.
  • [MeSH-minor] Humans. Male. Middle Aged. Prostate-Specific Antigen / blood. Salvage Therapy. Treatment Outcome. Urologic Surgical Procedures / methods

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18533232.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


78. Comstock CE, Knudsen KE: The complex role of AR signaling after cytotoxic insult: implications for cell-cycle-based chemotherapeutics. Cell Cycle; 2007 Jun 1;6(11):1307-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hormonal therapies that inhibit AR activity are the first line of intervention for disseminated disease, and are initially quite effective; however, recurrent, incurable tumors ultimately arise with restored AR function.
  • Given the importance of AR in governing the potentiation of this tumor type, there has been a dedicated interest in dissecting the mechanisms by which AR promotes prostate cancer proliferation and survival.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17568191.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA117846; United States / NCI NIH HHS / CA / R01 CA099996
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Androgen Receptor Antagonists; 0 / Androgens; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 0 / Apoptosis Regulatory Proteins; 0 / Cell Cycle Proteins; 0 / Mitosis Modulators; 0 / Neoplasm Proteins; 0 / Receptors, Androgen
  • [Number-of-references] 91
  •  go-up   go-down


79. Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M, Da Pozzo L, Bocciardi A, Rigatti P, Fazio F: Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol; 2007 Aug;52(2):423-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To prospectively evaluate the accuracy of integrated [(11)C]choline-PET/CT in the diagnosis of lymph-node recurrence in prostate cancer patients with biochemical failure after surgery.
  • Nineteen of the 21 patients (90%) with positive [(11)C]choline-PET/CT had nodal metastases of prostate adenocarcinoma at histologic evaluation.
  • CONCLUSIONS: [(11)C]Choline-PET/CT is an accurate diagnostic tool for the detection of lymph-node metastases of recurrent prostate cancer.
  • [MeSH-minor] Aged. Choline. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Recurrence, Local. Predictive Value of Tests. Prospective Studies. Prostate-Specific Antigen / blood. Prostatectomy. Radiopharmaceuticals. Tomography, Emission-Computed. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2007 Aug;52(2):429 [17397993.001]
  • [CommentIn] Eur Urol. 2007 Aug;52(2):310-2 [17376587.001]
  • (PMID = 17397992.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; EC 3.4.21.77 / Prostate-Specific Antigen; N91BDP6H0X / Choline
  •  go-up   go-down


80. Schwarz R, Krüll A, Tribius S, Alberti W: Results of three dimensional conformal radiotherapy and hormonal therapy for local recurrence after radical prostatectomy. Strahlenther Onkol; 2005 Jul;181(7):442-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: Analysis of treatment results of combined three-dimensional conformal radiotherapy (3DCRT) and hormonal therapy in patients with locally recurrent prostate cancer after radical prostatectomy.
  • PATIENTS AND METHODS: Between 1992 and 1998, 24 patients presented with a rising prostate-specific antigen (PSA) between 4 and 152 months following radical prostatectomy and a local recurrence demonstrated by imaging.
  • CONCLUSION: Radiotherapy and short-term adjuvant hormone therapy represent an effective and well-tolerated treatment for locally recurrent prostate cancer after radical prostatectomy resulting in good local control.
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Biopsy. Follow-Up Studies. Humans. Imaging, Three-Dimensional / methods. Male. Neoplasm Staging. Palpation. Retrospective Studies. Survival Analysis. Survivors. Time Factors

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15995837.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


81. Kortylewicz ZP, Nearman J, Baranowska-Kortylewicz J: Radiolabeled 5-iodo-3'-O-(17beta-succinyl-5alpha-androstan-3-one)-2'-deoxyuridine and its 5'-monophosphate for imaging and therapy of androgen receptor-positive cancers: synthesis and biological evaluation. J Med Chem; 2009 Aug 27;52(16):5124-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High levels of androgen receptor (AR) are often indicative of recurrent, advanced, or metastatic cancers.
  • Biodistribution and imaging studies show preferential uptake and retention of 8 and 13 in ip xenografts of human ovarian adenocarcinoma cells NIH:OVCAR-3, which overexpress AR.

  • BindingDB. BindingDB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1985 Sep;45(9):4206-14 [3875407.001]
  • [Cites] Urology. 1986 Sep;28(3):228-31 [3489307.001]
  • [Cites] J Steroid Biochem. 1987 Mar;26(3):393-7 [3495702.001]
  • [Cites] Radiat Res. 1989 Jun;118(3):532-44 [2727274.001]
  • [Cites] Med Phys. 1994 Dec;21(12):1901-15 [7700197.001]
  • [Cites] Int J Cancer. 1996 Jul 29;67(3):357-64 [8707409.001]
  • [Cites] Endocrinology. 1996 Oct;137(10):4126-9 [8828467.001]
  • [Cites] Cytometry. 1996 Dec 15;26(4):281-5 [8979027.001]
  • [Cites] Oncology. 1997 May-Jun;54(3):199-202 [9143399.001]
  • [Cites] Am J Obstet Gynecol. 1997 Jun;176(6):1319-26; discussion 1326-7 [9215191.001]
  • [Cites] Gynecol Oncol. 1998 Oct;71(1):3-13 [9784312.001]
  • [Cites] J Natl Cancer Inst. 1998 Dec 2;90(23):1774-86 [9839517.001]
  • [Cites] J Endocrinol Invest. 1999 Mar;22(3):223-34 [10219893.001]
  • [Cites] J Org Chem. 2007 Jul 20;72(15):5546-54 [17585812.001]
  • [Cites] Neuroendocrinology. 2007;86(2):84-93 [17684316.001]
  • [Cites] Hum Pathol. 1993 Jan;24(1):90-5 [8418017.001]
  • [Cites] J Biol Chem. 1990 Apr 15;265(11):6048-54 [2156840.001]
  • [Cites] Cancer Res. 1990 Sep 1;50(17):5382-6 [2386943.001]
  • [Cites] Endocrinology. 1991 Jul;129(1):436-45 [1675988.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Aug 30;179(1):90-6 [1883394.001]
  • [Cites] J Urol. 1992 Mar;147(3 Pt 2):798-803 [1371552.001]
  • [Cites] Radiat Res. 1992 Mar;129(3):309-14 [1542718.001]
  • [Cites] J Med Chem. 1992 May 29;35(11):2113-29 [1597861.001]
  • [Cites] Exp Cell Res. 1956 Aug;11(2):297-305 [13375651.001]
  • [Cites] Biochem Pharmacol. 1962 Feb;11:155-9 [13904241.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):893-903 [15585562.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Mar;32(3):344-50 [15726353.001]
  • [Cites] Cell. 2005 Sep 9;122(5):751-62 [16143106.001]
  • [Cites] BMC Cancer. 2005;5:148 [16293185.001]
  • [Cites] Virchows Arch. 2006 Jul;449(1):24-30 [16628414.001]
  • [Cites] J Hepatol. 1993 Feb;17(2):187-91 [8383159.001]
  • [Cites] Nucl Med Biol. 1993 Jul;20(5):597-606 [8358345.001]
  • [Cites] Appl Radiat Isot. 1994 Jul;45(7):795-801 [8061661.001]
  • [Cites] Eur J Cancer. 1994;30A(7):911-4 [7946581.001]
  • [Cites] Am J Epidemiol. 2008 Jan 15;167(2):211-8 [17982156.001]
  • [Cites] Future Oncol. 2008 Feb;4(1):15-21 [18240997.001]
  • [Cites] J Hum Genet. 2008;53(3):220-6 [18217192.001]
  • [Cites] Breast Cancer Res. 2008;10(1):R16 [18275596.001]
  • [Cites] Adv Exp Med Biol. 2008;617:223-34 [18497046.001]
  • [Cites] Adv Exp Med Biol. 2008;617:557-64 [18497082.001]
  • [Cites] J Nucl Med. 2008 Jun;49(6):987-94 [18483103.001]
  • [Cites] J Clin Oncol. 2008 Aug 20;26(24):3923-9 [18711180.001]
  • [Cites] Curr Opin Pharmacol. 2008 Aug;8(4):440-8 [18674639.001]
  • [Cites] Urol Int. 2008;81(3):353-9 [18931557.001]
  • [Cites] Int J Clin Oncol. 2008 Oct;13(5):431-5 [18946753.001]
  • [Cites] Endocr Relat Cancer. 2008 Dec;15(4):1061-8 [18772244.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2008 Dec;141(2):147-52 [18768247.001]
  • [Cites] Folia Histochem Cytobiol. 2008;46(3):269-76 [19056529.001]
  • [Cites] IUBMB Life. 2009 Jan;61(1):56-61 [19109827.001]
  • [Cites] Bioconjug Chem. 2009 Jan;20(1):78-86 [19117492.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):929-35 [10706107.001]
  • [Cites] BJU Int. 2000 May;85(7):932-44 [10792179.001]
  • [Cites] Br J Cancer. 2000 Oct;83(7):921-7 [10970695.001]
  • [Cites] J Urol. 2000 Dec;164(6):1992-5 [11061898.001]
  • [Cites] Nucl Med Biol. 2001 Jan;28(1):85-90 [11182568.001]
  • [Cites] Int J Cancer. 2002 Jun 10;99(5):652-7 [12115497.001]
  • [Cites] J Biol Chem. 2002 Jul 19;277(29):26618-22 [12015315.001]
  • [Cites] Int J Cancer. 2002 Aug 10;100(5):507-14 [12124798.001]
  • [Cites] Mol Cell Endocrinol. 2002 Jul 31;193(1-2):121-8 [12161011.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1174-81 [12192562.001]
  • [Cites] Radiat Res. 2003 Feb;159(2):251-61 [12537531.001]
  • [Cites] J Urol. 2003 Sep;170(3):990-3 [12913756.001]
  • [Cites] J Urol. 2003 Oct;170(4 Pt 1):1363-9 [14501770.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):725-31 [14608899.001]
  • [Cites] Steroids. 2003 Dec;68(14):1163-71 [14643878.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(4):294-300 [14663470.001]
  • [Cites] J Endocrinol. 2004 Jan;180(1):77-85 [14709146.001]
  • [Cites] J Cell Biochem. 2004 Feb 15;91(3):483-90 [14755679.001]
  • [Cites] Int J Biol Markers. 2003 Oct-Dec;18(4):273-9 [14756542.001]
  • [Cites] J Cell Biochem. 2004 Mar 1;91(4):662-70 [14991758.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11209-14 [15277682.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 May;130(5):253-8 [14963700.001]
  • [Cites] J Cell Biol. 1974 Nov;63(2 Pt 1):515-23 [4138144.001]
  • [Cites] Proc Natl Acad Sci U S A. 1974 Dec;71(12):4836-8 [4531021.001]
  • [Cites] J Steroid Biochem. 1975 Mar-Apr;6(3-4):437-42 [171494.001]
  • [Cites] Biophys J. 1976 Sep;16(9):1003-12 [963201.001]
  • [Cites] Biochem Biophys Res Commun. 1978 Feb 28;80(4):849-57 [637870.001]
  • [Cites] Int J Appl Radiat Isot. 1981 Nov;32(11):811-5 [7309270.001]
  • [Cites] Cancer Res. 1983 Nov;43(11):5379-89 [6604576.001]
  • [Cites] J Neurooncol. 1983;1(3):179-89 [6088714.001]
  • (PMID = 19653647.001).
  • [ISSN] 1520-4804
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / P41 GM103422; United States / NCRR NIH HHS / RR / P41 RR000954; United States / NCRR NIH HHS / RR / 2P41RR000954
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 5-iodo-3'-O-(17beta-succinyl-5alpha-androstan-3-one)-2'-deoxyuridine; 0 / 5-iodo-3'-O-(17beta-succinyl-5alpha-androstan-3-one)-2'-deoxyuridine 5'-monophosphate; 0 / Androstanols; 0 / Blood Proteins; 0 / Deoxyuracil Nucleotides; 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0 / Receptors, Androgen; 0 / Sex Hormone-Binding Globulin; W78I7AY22C / Deoxyuridine
  • [Other-IDs] NLM/ NIHMS557395; NLM/ PMC3941710
  •  go-up   go-down


82. Cocco E, Casagrande F, Bellone S, Richter CE, Bellone M, Todeschini P, Holmberg JC, Fu HH, Montagna MK, Mor G, Schwartz PE, Arin-Silasi D, Azoudi M, Rutherford TJ, Abu-Khalaf M, Pecorelli S, Santin AD: Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer. BMC Cancer; 2010 Jul 02;10:349
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Development of innovative, effective therapies against recurrent/chemotherapy-resistant ovarian cancer remains a high priority.
  • CONCLUSIONS: Based on the high levels of claudin-3 and -4 expression in chemotherapy-resistant ovarian cancer and other highly aggressive human epithelial tumors including breast, prostate and pancreatic cancers, CPE peptide holds promise as a lead peptide for the development of new diagnostic tracers or alternative anticancer agents.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5007-11 [11016619.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6281-7 [11103784.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6744-9 [11118061.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1176-81 [11158614.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3869-76 [11358798.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5895-904 [11479231.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):678-84 [11522752.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7878-81 [11691807.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):262-70 [11782386.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4722-9 [12183431.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):8-16 [12468336.001]
  • [Cites] Mol Carcinog. 2003 Feb;36(2):53-9 [12557260.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2567-75 [12855632.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):14-25 [15305371.001]
  • [Cites] Infect Immun. 1975 Aug;12(2):440-2 [168155.001]
  • [Cites] J Biol Chem. 1986 Feb 5;261(4):1801-7 [2418017.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):630-4 [7906395.001]
  • [Cites] Toxicon. 1996 Nov-Dec;34(11-12):1335-43 [9027990.001]
  • [Cites] J Cell Biol. 1997 Mar 24;136(6):1239-47 [9087440.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4334-42 [15899825.001]
  • [Cites] Virchows Arch. 2007 Sep;451(3):669-80 [17609977.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):7977-82 [17804705.001]
  • [Cites] Am J Obstet Gynecol. 2009 Jul;201(1):70.e1-9 [19426958.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • (PMID = 20598131.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-16359; United States / NCI NIH HHS / CA / R01 CA122728-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CLDN3 protein, human; 0 / CLDN4 protein, human; 0 / Claudin-3; 0 / Claudin-4; 0 / Cldn3 protein, mouse; 0 / Cldn4 protein, mouse; 0 / Enterotoxins; 0 / Membrane Proteins; 0 / Peptide Fragments; 0 / RNA, Messenger; 0 / enterotoxin, Clostridium
  • [Other-IDs] NLM/ PMC2908101
  •  go-up   go-down






Advertisement